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1. Foreword: Veterinary Transfusion Medicine 
 
Interest in veterinary transfusion medicine has been growing over the past few 
decades (Gibson, 2007). Increasing interest and availability of blood products 
has helped to make transfusion medicine a common practice at almost every 
veterinary clinic (Lavenschi et al., 2001; Lucas et al., 2004; Weingart et al., 2004; 
Hansen, 2006).  
Transfusion is defined as intravenous therapy with whole blood or blood 
products. Whole blood refers to blood that has not been separated into various 
products while blood products include blood components and blood derivates. 
Blood components are blood products prepared only by physical separation 
(centrifugation or sedimentation) while blood derivates are blood protein 
products prepared by using biochemical methods to process large pools of 
donor plasma. (Abrams-Ogg, 2000). 
The use of blood components allows several patients to benefit from one blood 
donation and reduces the risk of transfusion reactions to unnecessary 
components.  (Abrams-Ogg, 2000). 
Recent introduction in Italy of guideline provided by Ministry of Health (“Linea 
guida relativa all’esercizio delle attività sanitarie riguardanti la medicina 
trasfusionale in campo veterinario”,  pubblished in Supplemento Ordinario della 
Gazzetta Ufficiale Repubblica Italiana n.32 February 7, 2008) (Attachment n° 1) 
are likely to lead to further development of transfusion medicine and animal 
blood banking within in Italy.  
Knowledge and practice of appropriate blood collection, processing, storage and 
administration methods is essential for ensuring the safety of the donor and 
recipient, as well as maximizing the use of limited clinical resources.  
 
1.1 Donor selection 
1.1.1 Canine blood donors  
Canine blood donors should be healthy, good-tempered, between 1 and 8 years 
of age and a minimum bodyweight of 25 kg to allow collection of blood in 
standard human collection bags (Gibson et al., 2012). The donor should receive 
routine veterinary preventive health care including vaccination according to 
practice protocols. Dogs should not be receiving any medication at the time of 
donation with the exception of ectoparasite preventatives, routine worming 
medication and heartworm prophylaxis Donation should not take place with 10-
14 days of having received a vaccination. Any dog that has received a transfusion 
previously may have developed alloantibodies against different blood types and 
is unsuitable as a donor (Gibson et al., 2012).  
The Italian guideline for the suitability of canine donors is reported in 
Attachment n° 1.  
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The health of the donor should be assessed by a veterinary by careful review of 
clinical history, thorough physical examination and pre donation screening blood 
test. Pre donation tests include determination of blood type (at a minimum a 
DEA 1.1 status), annual haematology and serum  biochemistry profile, as well as 
screening for infectious diseases endemic to current or previous geographical 
location of the donor. Also screening of infectious agents that may have an 
impact on the health of the donor  (for example Dirofilaria immitis) is important 
to consider. Urinalysis and faecal examination for parasites are often 
recommended (Abrams-Ogg, 2000).  
In addition of the annual comprehensive health examination a complete donor 
history, physical examination and a complete blood count (CBC) should be 
performed prior of every donation to safeguard the health and assess the 
suitability of the donor (Gibson,  2007).  
The Italian guideline about screening test for canine donor is present in 
Attachment  n° 1. 
 
1.1.2 Feline blood donors 
Donor cats should be healthy large cats (> 5 kg of weight), between 2 and 8 
years of age and should be up-to-date with core vaccinations (feline calicivirus, 
herpesvirus and panleucopenia). Donor cats should be housed indoors to 
minimize fight wounds and infections.  Donor cats should not be on any 
medication other than those that prevent endo- and ectoparasites (Kohn et al., 
2012) .  
Italian guideline for the suitability of feline donors is present in Attachment n°1.   
A complete history of the donor should be taken before the donation. Annual 
laboratory evaluation consisting in CBC, serum biochemistry profile and 
infectious disease screening for feline leukemia virus (FeLV), feline 
immunodeficiency virus (FIV) and Mycoplasma Heamofelis is recommended in cats 
that donate regularly. Before each blood collection a CBC should be performed 
to safeguard the health of the donor (Kohn et al., 2012).   
The Italian guideline about screening test for feline donor is present in 
Attachement n° 1.  
 
1.2 Blood types 
Red blood cell types are determined by species specific inherited antigens 
present on the cell surface. Blood typing is important in transfusion medicine 
because of the risk of transfusion reaction (Abrams-Ogg, 2000).  
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1.2.1 Canine blood types 
Canine blood typing is currently classified using the Dog Erythrocyte Antigen 
(DEA) system. Within the DEA system there are six recognized antigen sites 
defined by the availability of international standardized antisera. This antigen 
sites are known as DEA’s 1.0, 3, 4, 5 and 7 and for all the DEA groups a dog 
may be positive or negative (Hale, 2012). Although not fully defined or 
recognized there are said to be upward of 18 or more antigen specificities 
described. In particular DEA 6 and DEA 8 are two examples of antigens that 
have been identified  but at this time no typing system is available. 
The DEA 1.0 system describes three antigens and a null phenotype. DEA 1.1 is 
the most common antigen in this system and is expressed by the red blood cells 
(RBCs) of 62% of dogs in different countries. DEA 1.2 and 1.3 are rarely 
identified. (Hale, 2012) 
The most antigenic blood type is DEA 1.1, however there are no naturally 
occurring alloantibodies against DEA 1.1. As such, most dogs will not 
experience a severe transfusion reaction from a first transfusion of DEA 1.1 
incompatible blood. However sensitisation occurs in the DEA 1.1 negative that 
receive DEA 1.1 positive cells. Antibodies (strong haemolysins and agglutinins) 
are produced which can cause an acute haemolytic transfusion reaction following 
repeated antigen exposure (e.g a second transfusion with DEA 1.1 positive 
blood) (Gibson, 2007). 
The principle of a serologic canine blood typing reaction is macroscopic 
agglutination to allow detection of the different RBCs surface antigens. As DEA 
1.1 is the most antigenic blood type it is strongly advised that the DEA 1.1 status 
of both the donor and recipient is determined prior to transfusion. DEA 1.1 
testing can be performed by a variety of methods (reference laboratory and in-
house testing).  
The card agglutination assay (RapidVet-H Canine, provided by DMS 
Laboratories, Flemington, NJ.) and immunochromatographic cartridge method 
(DME VET DEA 1.1, provided by Alvedia, Lyon, France.), performed by 
trained personnel, were suitable for in clinic emergency DEA 1.1 blood typing. 
There may be errors, particularly for samples from dogs with IMHA, and the 
immunochromatographic cartridge method may have an advantage of allowing 
typing of samples with persistent autoagglutination. Hover the laboratory gel-
based method (bID-Gel Test Canine DEA 1.1, provided by DiaMed, Cressier-
sur-Morat, Switzerland) is considered the gold standard method for canine blood 
typing and is used in reference laboratory (Seth et al., 2012). 
 
1.2.2 Feline blood types 
Blood groups in cats are described by the A-B system, which includes the blood 
types: A, B and AB. The blood types are inherited as a simple dominant trait, 
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with A being dominant over B. Genotypically type A cats are either homozygous  
a/a or heterozygous a/b, whereas type B cats are homozygous b/b. Type AB is a 
rare blood type in which a third allele is present, recessive to the a allele but 
dominant to the b allele. (Gibson,  2007). Typing of cats prior the transfusion is 
imperative because in cats naturally occurring antibodies are present in the 
plasma. These alloantibodies are isoagglutinins against the RBCs antigen that is 
not present in that individual cat.  These antibody are found in all type A and B 
cats after 2 months of age and their formation does not require prior exposure 
through transfusion or pregnancy (Gibson,  2007).  
The risk of transfusion reaction is greatest if a type B cat is given a type A blood, 
because almost all type B cats have high titres of anti A antibodies that result in 
rapid intravascular haemolysis of the donor RBCs. The transfusion reaction if a 
type A cat receives type B blood is usually less severe, resulting in accelerated 
destruction of the RBCs primarily due to extravascular haemolysis, because type 
A cats generally have weak anti-B antibodies that are usually of low titre.  
The rare type AB cats do not possess either alloantibody. Type AB cats should 
ideally receive type AB blood, but when that is not available type A blood is the 
next best choice. (Gibson, 2007).  
Most domestic short and long hair cats throughout the World are of blood 
group A with some geographical differences. Blood group B is more prevalent 
amongst particular purebred cats including the British Shorthair, Birman, Devon 
and Cornish Rex, Abissinian, Persian, Somali, Turkish Angora and Turkish Van 
(Day, 2012). 
The “gold standard” of feline blood typing remains the tube or microplate 
agglutination test (ID Gel-Test Micro Typing System, Diamed) but for routine 
use exist different commercial system (Proverbio et al., 2009, Day et al., 2012).  
The first in practice technology to be developed was a card-based system (DMS 
rapidvet-H feline, DMS Laboratories) with monoclonal anti A antibodies and 
triticum vulgari lectin as the B agglutinin (Proverbio et al., 2009). Most recently 
an immunochromatographic test (DMEVET Quick Test A + B, Alvedia) has 
been introduced (Day, 2012).   
 
1.3 Blood collection 
Blood can be collected from an open or closed system. A closed system is one in 
which the only exposure of the bag or its contents to air is when the needle is 
uncapped for venepuncture. For this reason closed system collection is preferred 
because it decreases the potential contamination of blood products and 
facilitates processing of blood components. Unfortunately closed systems do not 
guarantee a total sterility and  contamination can occur from cutaneous 
organisms even with aseptic venepuncture technique (Abrams-Ogg, 2000).  
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An open system is one on which there is one or more additional sites of 
potential bacterial contamination during blood collection or processing. Blood 
collection using syringes or empty collection or transfer bags with anticoagulant 
added at the time of donation are all classified to be open system. 
The anticoagulant-preservative solutions are important for the duration of time 
for which the whole blood or blood products can be stored and to support the 
glycolytic energy metabolism of RBCs to maintain their viability during storage. 
The anticoagulant solutions must often used are ACD (acid-citrat-dextrose), 
CPD (citrate-phosphate-dextrose) or CPDA-1 (citrate-phosphate-dextrose-
adenine). Multiple bag systems with empty transfer bags and red cell preservative 
(like SAG-Mannitol) may be used for component processing (Gibson, 2007).  
The volume of blood that may be collected safely from canine and feline donors 
is approximately 20% of their blood volume, every 3-4 weeks. The 
recommended volume limit is 18 ml/kg for dogs and 10-12 ml/kg for cats 
(Gibson, 2007, Spomberg, 2012).   
 
1.3.1 Canine blood collection 
Canine can safely donate approximately 15 to 20% of their overall blood volume 
every 3-4 weeks, equating to approximately 15-18 ml/kg. In general dogs do not 
requires sedation or anaesthesia and lie still for the collection process. The 
jugular vein is the recommended venepuncture site owing to the size and 
accessibility but also cephalic vein can be use in large giant dogs. Hair must be 
clipped from over the venepuncture site and the site must be prepare aseptically. 
Usually for collection of whole blood it is used commercially available collection 
bags (human closed system) that already contain anticoagulant and a swaged-on 
phlebotomy needle and are sterilized, sealed and protected in a plastic or foil 
overwrap.  Packs are also available with “satellite bags” for preparation of blood 
components (Gibson et al., 2012).  
Healthy dogs can safely make a donation into a 450 ml commercial blood bag 
with an allowable 10% variance (405-495 ml). By convention and for 
convenience a standard blood donation in dog with a minimum bodyweight of 
25 kg is 450 ± 45 ml, which is referred to as “one canine unit” (Abrams-Ogg, 
2000, Gibson et al, 2012). 
 
1.3.2 Feline blood collection 
Feline donors can safely donate 10-15% of body weight every 3-4 weeks, 
equating approximately 11-13 ml/kg. Unlike dogs almost all cats require sedation 
or anaesthesia for blood donation (for example with ketamine and midazolam or 
isofluorane/oxygen anaesthesia by mask). Blood is collected by jugular 
venepuncture with the cat restrained in either lateral or sternal recumbency 
(Gibson, 2007).  
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Closed systems for use in feline medicine are currently not available. For this 
reason blood is commonly collected with a 19 G winged infusion set 
(“butterfly”) attached to a 60 ml syringe into which the anticoagulant-
preservative solution has been drawn (open system). For blood banking purpose 
the blood is then transferred to a 100-150 ml storage bag. A standard donation 
in the cat results in 60 ml of anticoagulated blood (53 ml of blood and 7 ml of 
anticoagulant, often CPDA1) (Kohn et al., 2012).  
 
1.4 Blood components 
The optimal transfusion therapy is performed by selection of the most 
appropriate blood component and administration of that component in the 
manner most likely to avoid transfusion reaction. The principle of component 
therapy consists in dividing whole blood into its single elements, mainly packed 
red blood cells and plasma by centrifugation. (Gibson et al., 2012).  
 
1.4.1 Whole blood 
Whole blood can be used fresh (FWB) with the transfusion carries out within 8 
hours of collection. In this case all blood components (red blood cells, platelets, 
labile and stable coagulation factors, plasma proteins) are present and functional. 
Whole blood can also be stored in a refrigerator at 1-6 °C for variable days 
depending on the anticoagulant-preservative used. The unit is then classified as 
storage whole blood (SWB) which will differ only form FWB by the functional 
reduction of labile clotting  factors and platelets.  
The small blood volume collected, the use of on open collection system and the 
difficulties in separation of blood elements make FWB and WB transfusions still 
the norm in feline patient (Gibson et al., 2012).  
  
1.4.2 Packed red blood cells 
The PRBCs is obtain from whole blood by separation from the plasma by 
centrifugation (preferably) or sedimentation. Blood component processing 
requires variable speed, temperature-controlled centrifuges to produce products. 
The precise centrifugation protocol used depends on the centrifuge but the 
separation of WB into PRBCs and plasma  typically requires centrifugation at 
5000g for 5 minute (not including deceleration time) at 4°C. (Gibson, 2007). 
Once the donor unit has been centrifuged and the red cells separated from the 
plasma with the use of a plasma extractor a nutrient solution such as Optisol is 
added to PRBCs and the units are stored under refrigeration at 1-6°C. The PCV 
of the unit is grater than that of the whole blood because it will have been greatly 
concentrated (70-80% without added nutrient solution) with the volume yield 
dependent on the donor PCV. The storage time of PRBCs can vary from 3-6 
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weeks depending on the type of anticoagulant and nutrient solution use (Gibson 
et al., 2012).   
 
1.4.3 Fresh plasma, fresh frozen plasma and frozen plasma.  
Fresh plasma is plasma that has been separated from RBCs within 8 hour of 
collection and immediately transfused (Abrams-Ogg, 2000).  
Fresh frozen plasma (FFP) is plasma that has been separated and placed at -18°C 
or colder within 8 hours of collection. These time restrictions are based on the 
deterioration of human factor VIII activity and other labile clotting factors such 
as factor V and vWF.  Fresh plasma and FFP contain plasma proteins, albumin 
and globulins and have maximal activity of all coagulation factors. After 1 years 
storage period FFP is relabelled as frozen plasma (FP), which may be stored as 
such for additional 4 years at - 18°C or colder. The 1 years expiry date for FFP is 
also based on the deterioration of FVIII activity. FP can be also obtain if the 
unit of plasma has been prepared after 8 hours of collection. This product 
contains all the vitamin k dependent coagulation factors (II, VII, IX, X), 
immunoglobulins and albumin but is relatively devoid of the labile clotting 
factors. FP has a shelf life of 5 years after the original date of collection or 4 
years after expiration of a unit of FFP (Gibson et al., 2012). 
  
1.4.4 Platelet rich plasma (PRP) and platelet concentrate (PC) 
PRP and PC may be prepared from FWB. FWB is centrifuged on “light” spin.  
The speed and time centrifugation are lower than those typically used to separate 
PRBCs and plasma, and the product is not refrigerated. The PRP and PC may be 
stored at 20-24 °C with gentle continuous or intermittent agitation, for 5 days 
when collected using a closed system. Given that the storage temperature is 
higher than that used for other blood products, platelet products are more 
susceptible to bacterial contamination, and if collected in an open system, they 
should be used within 4 hours of collection. Unfortunately the difficulties 
associated with their production often result in the use of more readily available 
fresh whole blood (Gibson et al., 2012).     
 
1.5 Storage of blood components containing RBCs 
RBCs stored under blood bank conditions undergo structural and functional 
deterioration, collectively referred to as RBC storage lesions. Most of the lesions 
are the result of the progressively effect RBC metabolism and are reversible in 
vivo. On the other hand, the structural changes and the loss of membrane are 
permanent and probably related to in vivo RBC survival and the adverse effects 
of transfusion. Although some differences in the aging profile between in vivo 
and ex vivo conditions have been reported, a part of stored RBCs progressively 
express some of the typical marks of senescence and erythrophagocytosis, like 
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the formation of Band 3-IgG complexes, the exposure of PS, and the 
spheroechinocytosis. The increasing accumulation of aging effects in a part of 
the transfused RBCs contributes not only to their rapid elimination but also to 
the various adverse side effects of the transfusions. (Antonelou et al., 2010). In 
fact recent human studies have demonstrated that there may be a correlation 
between the number of days of cold storage of packed red blood cells (PRBC) 
and adverse outcomes, including mortality, among transfused patients, 
presumably due to structural or functional changes in RBCs that occur during 
storage (Vandromme et al., 2009, Napolitano et al., 2004). 
Blood products containing RBCs (PRBC or SWB) have a short lifespan and are 
marked with a maximal expiration date (usually 28–35 days for canine RBCs), at 
which point storage lesions may compromise the function and viability of the 
cells. Due to these changes the addition of nutrient and preservative solutions is 
imperative to help increase red cell viability. Even with additional preservative 
solutions and optimal storage conditions, the quality of RBC products declines 
with time (Antonelou et al., 2010, Spromberg, 2012).   
RBCs require oxygen and nutrient for survival and during the storage the 
amount of viable RBCs reduces over time. When red cells within the unit 
become inactive and die, they are broken and release potassium and ammonia as 
a by-product (Abrams-Ogg 2000). In stored PRBCs deamination of adenine 
(often present in preservative solutions), and plasma and intraerythrocytic 
protein leads to the formation of ammonia.  Ammonia increase to extremely 
high concentration in units of canine PRBCs stored in CPD-Adsol over the 
accepted time period of 35 days. Besides seems that the kind of storage (small 
refrigerator open frequently or large blood-banking refrigerator not open more 
than once a day) could further affected the ammonia concentration (Waddell et 
al., 2001).  Hyperammoniemia can pose a problem for animals which underlying 
hepatic disease as they are unable to fully filter out ammonia and its 
accumulation in the hepatic patient can lead to exacerbation of the hepatic 
disease, CNS symptoms and hepatic encephalopathy (Gibson, 2012).  
Due to the potential deterioration of activity and function of labile blood 
components, conditions of storage and time prior to processing are vital to the 
preparation of components. Delays in preparation or unsuitable conditions of 
storage may adversely affect quality of the final components (Gibson et al., 
2012). 
 
1.6 Aspects of red cell preservation 
The anticoagulant solutions used in blood collection have been developed to 
prevent coagulation and to permit storage of red cells for a certain period of 
time. While originally designed for whole blood storage, they have also been 
used in blood from which components are prepared. 
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All of the solutions contain sodium citrate, citric acid and glucose, some of them 
may also contain adenine, guanosine and phosphate. Citrate binds calcium and 
prevents clotting of the blood. Glucose is used by the red cell during storage and 
each glucose molecule gives 2 molecules of adenosine tri phosphate (ATP) 
which is formed by phosphorylation of adenosine di phosphate (ADP) (Abrams-
Ogg, 2000).   
An additive solution should allow maintenance of red cell viability even if more 
than 90% of the plasma is removed. The use of glucose and adenine is necessary 
for the maintenance of red blood cell posttransfusion viability, phosphate may 
be used to enhance glycolysis, and other substances may be used to prevent in 
vitro haemolysis (i.e.mannitol, citrate). Sodium chloride or di-sodium phosphate 
may be used to give the additive solution a suitable osmotic strength (Abrams-
Ogg, 2000). 
The duration of storage may vary with the type of preparation (concentration of 
cells, formula of anticoagulant, use of additive solution, etc.) and should be 
determined for each type on the basis of achieving a mean 24 hours post 
transfusion survival of no less than 75% of the transfused red cells (Abrams-
Ogg, 2000). 
 
 
1.7 Contamination of blood and components 
Ensuring the safety of whole blood and blood components is of the utmost 
importance in transfusion medicine. Source of microorganism include donors 
(bacteraemia and skin flora) and contaminated blood collection, banking and 
transfusion supplies.  
Infectious screening of the donors is crucial to assure the quality of blood 
components but there is always the potential that the donors can have a 
subclinical viremia, bacteraemia or parasitemia and that the organisms could be 
transmitted via transfusion to a patient. Besides bacterial contamination can be 
iatrogen occurring during all steps to obtain and use a blood product (collection, 
processing, storage and administration). 
The risk of transfusion-associated sepsis using human blood bag is low. The 
organism implicated most often in human are Yersinia enterocolica, Pseudomonas spp, 
Staphylococcus spp, Streptococcus spp and various Gram-negative organism (Abrams-
Ogg, 2000).  
Often in veterinary medicine bacterial surveillance programs  are not used 
despite in human medicine blood transfusion therapy has emerged as a potential 
source of iatrogenic septicaemia. While exists a great literature about 
contamination of whole blood and blood components in human medicine the 
prevalence of microbial contamination and organism in veterinary transfusion 
medicine are poorly documented (Abrams-Ogg, 2000). The only two article 
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about contamination of blood bags in veterinary medicine regard feline units 
obtained with open system.  
One publication (Hohenaus et al, 1997) reported the contamination of many 
feline units by Serratia marcescens. The units were contaminated during the 
collection via the saline flush used for sedation of feline donors and resulted in 
recipient morbidity and mortality.  
In another study (Kessler et al, 2010) a feline PRBCs unit turned black after 22 
days of storage and result  positive for Pseudomonas fluorescens. In this study source 
was not found and no other contaminated units were identified.  
In veterinary blood banking aseptic collection, temperature controlled storage 
and a visual monitoring of stored units is recommended. Discolored units 
should not  be transfused, but examined for bacterial contamination or other 
blood product quality problems (Hohenaus et al, 1997, Kessler et al, 2010).   
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2. Evaluation of hematological parameters, 
ammonia concentration and microbial 
contamination in Canine Packed Red Blood Cells 
stored in CPD-SAGM for 42 days.  
 
2.1 Abstract 
Canine transfusion medicine practices have been growing rapidly over the past 
few decades and the use of specific blood components (packed red cells, plasma) 
has permitted to optimized the canine blood donations. The study was  
undertaken to evaluated the changes in RBC, MCV, Ht, RDW, WBC and 
ammonia concentration in canine PRBC stored in CPD-SAGM  for 42 days. 
Also the presence of bacterial contamination was evaluated with blood culture. 
PRBC units were stored in a routine manner and were examined every 2-3 
weeks. Hematological parameters changed significantly with increase of MCV, 
Ht and RDW, while WBC decreased. Also ammonia concentration increased 
significantly during the storage. RBC and WBC deteriorated somewhat during 
storage and ammonia concentration increased similar to what reported in canine 
and human in vitro studies. No bacterial contamination was reported. The 
results obtained in this study agree mostly with what previously is reported in 
canine and human medicine. Further studies are needed to better evaluated how 
the reported  alterations influence viability of blood cells in canine PRBC.  
 
2.2 Introduction 
The primary purpose of transfusion therapy is to replenish the specific blood 
component  that is diminished. Due to improvement in component preparation 
technology the use of stored blood components has become common practice 
also in canine transfusion medicine (Lavenschi et al., 2001; Lucas et al., 2004; 
Hansen, 2006).The use of blood components permits to optimize the blood 
donation and to reduce the risk of transfusion reactions to unnecessary 
components. In canine species blood components can be obtained by human 
commercially available multiple bag systems containing various additive 
solutions.  
During storage erythrocytes undergo some complex structural, functional and 
metabolic alterations which are called “storage lesion” even if many effort have 
been made to improve the quality of RBC units and prolong their shelf life (like 
inline filter to remove leucocytes before storage and new additive solutions) 
(Zehnder et al., 2008). These storage lesions of RBCs (red blood cells) may 
explain why their capacity of oxygen-delivery and tissue oxygenation is reduced.  
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Recently in human medicine in some studies (Napolitano et al., 2004, 
Vandromme et al., 2009) the duration of RBC storage before transfusion may be 
related to morbidity and mortality in critically ill patients and after cardiac 
surgery.  
Moreover during storage of PRBC and whole blood units also the environment 
within the bag undergoes changes like pH and dextrose concentration decrease, 
while lactate and ammonia concentration increase (Hess et al., 2000, Waddell et 
al., 2001). 
Another important aspect related to blood components is the possible bacterial 
contamination that can be endogenous (transient bacteriemia of the donor) or 
exogenous (inadequate skin sterilization, contamination of collection bag, and 
anticoagulant) and that may occur during the blood collection, the preparation 
and storage of blood products and their administration.  In human medicine, the 
problem of bacterial contamination is well known (Brecher et al., 2005, Lee, 
2011) with an incidence between 0,002% and 1% for PRBC (D’antonio et al., 
2002) while the veterinary literature is scarce and relating exclusively to the feline 
species (Hohenhaus et al., 1997, Kessler et al., 2010). Despite the lack of 
reported cases of bacterial contamination in canine transfusion medicine it is 
importance to use a correct protocol to prevent the problem. 
The aim of this research was to investigate the safety of canine PRBC stored for 
42 days in CPD-SAGM (citrate-phosphate-dextrose-saline-adenine-glucose-
mannitol) and to evaluate the modification of hematological parameters and 
ammonia concentration during storage. 
 
2.3 Materials and Methods 
 
All units of whole blood were obtained with informed owner consent from dogs 
enrolled as donors in the community volunteer canine donor program of the 
Reparto Emotrasfusionale Veterinario (REV) of Veterinary Faculty of Milan.  
All donors were healthy, good-tempered, 2-8 years old,  and with a minimum 
weight  of 25 kg. All donors have had annual physical examinations and 
vaccinations, regular flea and tick control and heartworm prophylaxis. All dogs 
were submitted to blood group typing (Lab Test Canine DEA 1.1 Blood Typing, 
Alvedia, Lyon, France) and annual screening includes a complete blood count 
(CBC), serum chemistry panel, urinalysis, faecal exam and  testing for the 
following infectious diseases: Leishmania infantum (IFAT, Leishmania-Spot IF, 
Biomerieux), Ehrlichia canis (IFAT, Fluo Ehrlichia canis, Biopronix), Rickettisia 
conori (IFAT, Fluo Rickettsia conori, Biopronix), Babesia canis (evaluation on 
blood smear), Dirofilaria immitis antigen (SNAP HTWM, Ideex Laboratories) and 
D. immitis microfilariae. Dogs were excluded as donors if they had hematologic 
or biochemical abnormalities, evidence of systemic abnormalities on physical 
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examination, positive serological results (≥ 1:80) for L. infantum, E. canis or R. 
rickettsii, a positive test result for D. immitis antigen and/or microfilariae or a 
positive smear for Babesia canis. In case of doubt in the evaluation of infectious 
disease the result was confirmed submitted an EDTA-blood sample to PCR test.  
Prior to every donation recent history was taken from the owner, a physical 
examination was performed and a small sample of blood in EDTA was obtained 
to performed a CBC (Cell-Dyn 3500Plus, Abbott Diagnostics, Germany) for 
ensure the safety of the donor. All the dogs were fasted for up 12 hours prior to 
blood collection in attempt to minimized nausea and to prevent lipaemia in the 
collected blood.  
 
2.3.1 Blood collection 
All equipment was prepared and arranged prior to starting the donation 
procedure.  
For all donations was used a sterile triple-pack blood collection system (CPD-
SAG Mannitol Grifols Triple K.S., Grifols, Barcelona, Spain) to obtain from 
whole blood donation 2 different products (Packed red blood cells –PRBC – and 
Fresh Frozen Plasma – FFP-) and a blood scale and shaker (Delcon Hemotek 2, 
Italy) which rocks the blood during gravity collection and clamps the tubing 
when the bag reaches a desired weight.  The donation session required the 
participation of 3 people (minimum 2 vets) – one phlebotomist and two 
adequately trained personnel to restrain and monitor the donor, as well as to 
assist with handling of the collection equipment during the donation.  
The dog was restrained securely and comfortably on a table to facilitates 
comfortable restraint for the period of approximately 10-15 minutes required for 
the blood collection. The venipuncture site corresponding to the cephalic vein 
was shaved and prepared aseptically with ethanol (ethanol 94°, ACEF S.p.a.). 
The volume of blood collected was 450 ml, with an allowable 10% variance 
(405-495 ml). 
  
2.3.2 Care at the donor after donation  
The dog was observed for 15-20 minutes for weakness, pale mucous membrane, 
weak pulse and other signs of hypotension. Dog was offered water and food 
during the post donation observation period. The owners were advised to avoid 
exercising the dog excessively for several days.  
 
2.3.3 PRBC preparation 
RBCs were separated from plasma within 6 hour of collection using a blood 
centrifuge (Rotixa 50 RS –Hettich, Germany ). The blood centrifuge was set at a 
temperature of 4° C, 3500 RPM with initial acceleration (run up 9) and free 
deceleration (run down 0) for 25 minute.  At the end of centrifugation the 
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plasma had been extracted with a manual plasma extractor (Separation Stand 
Teruflex ACS-201) and put into the first empty satellite bag. To prepare PRBC 
the seal of the preservative solution bag (SAG-M) was opened and the solution 
was transferred for gravity into the primary bag containing the RBCs. Once the 
preservative has transferred completely the bag was  gently rocked back and 
forth to ensure adequate mixing. Using a manual stripper the blood remaining in 
the tubing was stripped into the bag, the bag was gently manually mixed and 
compressed to refill the tubing. This procedure was made 3 or 4 times to have a 
correct distribution of PRBC into the tube.  The tubing was sealed with a 
thermal sealers (Hemoweld B-Delcon, Italy) to provides 6 aliquots of about 0.5 
ml (tubing 10 cm long) which were used to performed test. 
 
2.3.4 Storage of PRBCs 
All bags were labelled with the date, the type and volume of the product, 
identification number of the donor, blood type, collection and expiration date. 
One aliquot of PRBC was taken immediately before the storage to performed 
hematological test and measured ammonia concentration  at day 0 (D0) and one 
aliquot was taken the day before for blood culture. The units were  stored in a 
specialized blood storage refrigerator with built-in temperature alarm at 4°C ± 
2°C (Emoteca 250, Fiocchetti, Luzzara, Italy). The bags were posed vertically to 
reduce the risk of damage and to maximize oxygen diffusion in to, and carbon 
dioxide diffusion out of, the bag. To ensure a uniform distribution of the 
anticoagulant solution and increase the viability of red blood cells the bags were 
manually massaged and gently mixed three - four times per week. 
 
2.3.5 Hematological parameters and ammonia concentration 
Every 2 weeks starting from D0  and  until the expiry at D42 an aliquot of 
PRBC was used to perform test. 
Before performing tests the aliquot was manually mixing for 1 minutes, after this 
the sample was take with a 27 gauge needle and syringe and put in an eppendorf 
tube. The eppendorf tube was gently mixed 2-3 times before measure ammonia 
with an automated tool (Ammonia Checker II model AA-4120, Menarini, Italy) 
and a special test strip (Ammonia Test Kit II, Menarini Italy). The remaining 
sample was put on a blood rocker for minimum 5 minutes before performing 
CBC (Cell-Dyn 3500 PLUS, Abbott Diagnostics, Germany).   The same 
procedure was made at D14, D28 and D42. 
 
2.3.6 Blood culture 
During a period of 6 months 10 PRBC units were randomly chosen for blood 
culture. The culture was performed at D1, D21 and D42 using for each culture 
an aliquot of stored PRBC. The culture was performed using a modified and 
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adapted standard microbiological procedures (Carter et al., 2004). An amount 
ranging from 200 to 500L of blood was seeded in sterile way in a culture broth 
(Tryptic Soy Broth, TSB, Oxoid, Italy) in a 1:10 ratio. The tube was then 
incubated at 37°C for 24 hours; if after this period, the broth was clear, with 
packed red cells on the bottom, the tube was again incubated for 24 hours up to 
a maximum of 72 hours; over this period the sample was indicated as sterile. On 
the contrary in case of turbidity of the culture medium, index of positivity, 100  
L of sample was transplant on solid medium agar-blood, which is obtained by 
adding defibrinated sheep blood to base medium Tryptic Soy Agar (TSA) 
(Microbiol, Italy). This solid culture medium allows to obtain colonies with the 
macroscopic morphology typical of the various bacterial species. Then the plate 
was incubated at 37 ° C also for 24 hours, after which it was proceeded to the 
identification of bacteria by macro-and microscopic examination (evaluation of 
macroscopic morphology and execution of the Gram stain), construction of 
simple biochemical tests and transplantation on selective and differential culture 
medium (Quinn et al., 2002; Carter et al., 2004; Poli et al., 2005; Jones, 2006). 
Also visual inspection of color of the PRBC contained in the bags was made to 
research possible signs of contamination.  
 
2.4 Statistical Analysis 
Data analysis was performed using a commercial statistical software (MedCalc 
Software, Mariakerke, Belgium). Data were tested for normality using the 
Kolmogorov-Smirnov test and mean ammonia concentration, means of Red 
Blood Cells count (RBC), White Blood cells count (WBC), Mean Cell volume 
(MCV), Hematocrit (Ht), Red cell Distribution Width (RDW) at each sampling 
point were compared using a one way repeated measures ANOVA. Correlation 
of MCV and Ht was evaluated by Spearman’s Coefficient. A p value of < 0.05 
was considered statistically significant. 
Hemoglobin has not been considered in the statistical analysis because the  
automated hematology analyzer used in this study, CELL-DYN 3500 PLUS, 
lyses red blood cells to determine the amount of hemoglobin. In this way the 
analyzer can not distinguishing among the hemoglobin present in the plasma and 
resulting from the normal in bag hemolysis and the hemoglobin contained inside 
the red blood cells. Because MCH and MCHC are calculated by the analyzer 
starting from hemoglobin also these 2 parameters are excluded by the statistical 
analyses. 
 
2.5 Results  
A total of 33 canine PRBC units were subject to evaluation of hematological 
parameters at D0, D14, D28 and D42. Mean and standard deviation of all 
parameters are reported in Table 1.  
28 
 
There was no significant change in RBC during storage period (p = 1) (Graph 1).  
All other parameters evaluated showed statistically significant differences during 
the time points. In particular there was:  
- a significant increase  in Ht between D0 and D 42 (p = 0.0003) and between 
D14 and D42 (p = 0.002) (Graph 2)  
- a significant and progressive increase of MCV during all time points, in 
particular between D0 and D14 (p= 0.0353), between D0 and D 28 (p=0.0002), 
between D0 and D 42 (p < 0.0001), between D 14 and D28 (p= 0.0001), 
between D14 and D 42 (p < 0.0001) and between D28 and D42 (p= 0.0011) 
(Graph 3) 
- a significant increase of RDW between D0 and D42 (p < 0.0001), between 
D14 and D42 (p < 0.0001) and between D28 and D42 (p = 0.0005) (Graph 4). 
Our analyzer (Cell-Dyn 3500 Plus, Abbott Diagnostics) permits to obtain WBC 
with 2 different method: impedance measurement (WIC) and optical counting 
(WOK ) of leukocytes. The WBC values measured with both methods have 
showed extremely different counts during all storage time. In particular WIK 
showed an increase in WBC during the storage and WOK a decrease during 
storage. After the evaluation of some smears obtained from the same PRBC 
units at D0, D14, D28, D42 we have considered more reliable the laser count 
(WOC). In fact analyzing blood smears the leukocytes were reduced in number 
with the passage of time and appeared often as lysed cells (Figure 1).  
Statistical analysis of WBC (optical count with laser) showed  a significant 
decrease of WBC between D0 and D14 (p < 0.0001), D0 and D28 (p < 0.0001), 
D0 and D42 (p < 0.0001), D14 and D28 (p = 0.0001), D14 and D42 (p = 
0.0004), but not significant between D 28 and D42 ( p = 1) (Graph 5).  
Also a statistically significant and positive correlation was evident between Ht 
and MCV at D0 (rho = 0.420, p = 0.0150), at D28 (rho = 0.658, p < 0.0001) and 
at D42 (rho = 0.628, p = 0.0002).  
A total of 30/33  units of PRBC were subjected to determination of ammonia 
concentration at D0, D14, D28, D42. Mean and standard deviation are reported 
in table n°1. Statistical analysis showed a significant and progressive increase of 
ammonia during all time points (p < 0.0001) (Graph 6).   
No PRBC unit of 10 randomly chosen showed bacterial contamination or 
changes in color at D0, D21 and D42.  
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Table 1: RBC, Ht, MCV, RDW, WBC (in 33 PRBC units) and ammonia concentration (in 30 PRBC 
units) in canine PRBC stored in CPD-SAGM for 42 days.  Mean ± standard deviation  
 
Time 
points 
RBC  count 
(x 10³/µL) 
Ht (%) MCV (fL) RDW (%) WBC count 
(/µL)  
NH3 
(µg/dL) 
D0 9030,6667 ± 
168,6423 
54,8667 ± 
1,1069 
60,8000 ± 
0,5111 
15,6152 ± 
0,2032 
11701,5625 ± 
798,7550 
39,7296 ± 
6,0139 
D14 9074,3333 ± 
251,0002 
55,9800 ± 
1,5609 
61,9758 ± 
0,5753 
15,9364 ± 
0,2005 
2928,0938 ± 
423,7766 
260,7921 ± 
12,5268 
D28 9016,0000 ± 
215,7380 
56,7797 ± 
2,3123 
64,6879 ± 
0,7599 
16,0303 ± 
0,2215 
782,6563 ± 
96,0858 
342,4568 ± 
16,0945 
D42 9002,6667 ± 
250,9462 
61,7267 ± 
1,9488 
68,1879 ± 
0,8813 
17,9030 ± 
0,4375 
855,8312 ± 
234,2504 
423,8443 ± 
12,6180 
 
Graph 1: RBC (x 1000/µL) in canine PRBC stored in CPD-SAGM for 42 days. 
 D
0
D1
4
D2
8
D4
2
 
Graph 2: Ht (%) in canine PRBCs stored in CPD-SAGM for 42 days. 
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Graph 3: MCV (fL) in canine PRBC stored in CPD-SAGM for 42 days. 
 D
0
D1
4
D2
8
D4
2
 
 
Graph 4: RDW (%) in canine PRBC stored in CPD-SAGM for 42 days. 
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Graph 5: WBC in canine PRBCs stored in CPD-SAGM for 42 days (laser count). 
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Graph 6: Ammonia concentration in canine PRBCs stored in CPD-SAGM for 42 days 
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Figure 1: Blood smear of canine PRBC in CPD-SAGM at D0 and D42 (x1000 magnification)  
1a: presence of some macrocytes at D0 
  
 
1b: presence of some lysed cell (red blood cells and one leukocyte) at D42 
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2.6 Discussion  
Our study has investigated the effects of storage in canine PRBC preserved in 
CPD-SAGM solution for 42 days on some hematological (RBC, Ht, MCV, 
RDW, WBC) and biochemical (ammonia concentration) parameters. In 
veterinary medicine few studies have evaluated hematological parameters in 
stored whole blood or stored PRBC cells (Wardrop et al., 1997, Mudge et al., 
2004, Ekiz et al., 2012).   
In our study RBCs did not show significant differences during the storage, like 
reported in canine (Ekiz et al., 2012) and in human studies (Garritsen et al., 
2003). Probably this is due to the fact that the majority of red blood cells 
maintained their integrity during the storage.  
All the other hematological parameters evaluated in our study showed significant 
difference during the storage.  
The significant increase of Ht during the storage time is comparable to what 
reported in a recent study (Ekiz et al., 2012) on canine PRBC stored in SAGM 
but it is different from what reported from other studies in animals (Wardrop et 
al., 1997, Mudge et al., 2004). In particular Wardrop et al. (1997) evaluated 
canine PRBC stored in 2 different solution (CPDA 1 and Nutricel) for 35 days 
and did not show significant increase of Ht during storage time. Similar data 
were reported in a study  in which  Ht of equine blood stored with ACD, CPD 
and CPDA1 were relatively constant throughout the storage (Mudge et al., 2004).   
Moreover the mean value of Ht in our PRBC units at D0 (54,86% ) is lower 
respect what reported by Wardrop et al. (1997) in canine PRBC (63% in Nutricel 
PRBC, 74% in CPDA1PRBC) and higher respect what reported by Ekiz et al. in 
canine PRBC (2012) (38,89%  in SAGM PRBC). The Ht of PRBC units may 
vary depending on the Ht of the donor, diluting effects of the additive solutions, 
and the amount of plasma volume in the bag.  
In our study also MCV is statistically  increased during storage like reported in 
other studies (Tuner et al. 1987 , Arduini et al., 2007, Ekiz et al., 2012,). In 
particular Ekiz et al. (2012), showed a significant increase in MCV during storage 
of canine PRBC with SAGM starting to a MCV of 66,67fL and arrived at D28 to 
a value of  69.93 fL. In our study the increase in MCV was higher with a 
difference between D0 and D42 of 7.4fL.  A little change in MCV is also 
reported in human blood stored for 42 days in CPDA1 (Turner et al, 1987). In 
this study the authors report that this “swelling ” phenomenon is presumably 
due to the accumulation of CPDA1 metabolites and that the incubation of the 
samples for 24 h in fresh plasma (and presumably reinfusion in vivo) apparently 
reverses the effects of this secondary cell swelling phenomenon and results in 
the production of shrunken cells.  
Also in another human study conducted by Arduini et al. (2007) erythrocytes 
preserved in SAGM  present an increase of MCV during storage. The MCV 
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increase is correlated in part to the use of SAGM that  produce RBC swelling 
(Zehnder et al., 2008) and in part it is the consequence of substances products by 
leukocytes, which are known to affect erythrocyte membrane properties. In fact 
Ekiz et al. (2012) reported that MCV was lower in leukoreduced canine PRBC 
units. 
However our data is different from what reported by Mudge et al. (2004) in 
which MCV did not vary consistently with time of storage for equine blood 
stored with ACD, CPD and CPDA1. The differences of our study with the 
study conducted by Mudge et al. (2004) is probably due in part to the different 
species and in part to the different anticoagulant-preservative used.  
In our study, Ht and MCV increased steadily during storage and was highlighted 
a positive correlation between these two parameters. In fact, since RBC 
remained constant during storage the increase of Ht is correlated to the increase 
in the volume of red blood cells (MCV).The same correlation was also 
highlighted by a study of human medicine conducted by Garritsen et al. (2003) 
on 2 different kind of packed red cells in SAGM.  
In our study also RDW value is statistically higher at the end of the storage like 
reported in Ekiz et al. (2012). This increase during storage might be an indicator 
of red blood cells changes during storage (Photo 1). In fact the RBC 
morphology shifted towards echinocytosis during storage (Zehnder et al., 2008). 
In this case our value of RDW are similar to what reported from Ekiz el al. 
(2012). 
Finally, in our study, WBC (laser count) has undergone a rapid and statistically 
significant reduction in storage. It is in fact known that the very short duration 
of life of granulocytes does not allow the storage and transfusion of this product 
(Kohn et al., 2012). Our data concerning WBC does not agree with those 
reported by Ekiz et al. (2012). In the study of Ekiz et.al in canine PRBC without 
leukoreduction WBC count increased from 15930/µL at D0 to 16200/µL at 
D35 with a statistically significant difference. However in the study of Ekiz et al. 
(2012) the type of automatic analyzer used for the counts is not reported. The 
analyzer used in our study (Cell-Dyn 3500, Plus) allows two methods to count 
leukocytes, impedance and laser. The first method gave us an increase of WBC 
during the storage while the second method gave us a decrease of WBC during 
storage. In our study on the basis of what has been shown by some smears 
obtained from the PRBC units the laser count has been considered to be  closer 
to reality (characterized by the lysis of the majority of white blood cells during 
storage). Based on this we can not compare our data with the study of Ezik et al. 
(2012).  
Unfortunately, our automated analyzer did not allow us to quantify correctly the 
Hb and consequently the parameters calculated from it (MCH and MCHC). 
Furthermore, the amount of sample remaining after CBC and measurement of 
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ammonia was not sufficient to measure the free hemoglobin on supernatant after 
centrifugation. Percentage of hemolysis during storage is an important parameter 
for the evaluation of the quality of stored whole blood or PRBC units (Arduini 
et al., 2007, Garretsen et al., 2003) and will be evaluated in further studies. 
 In our study we also measured the concentration of ammonia that is increased 
to extremely high concentrations like reported by Waddell et al. (2001) that 
evaluated ammonia of canine PRBC in CPD-Adsol over the period of 35 days. 
The ammonia concentration in our study is similar at D0 (39,73 ± 6 µg/dL) and 
D14 (260,79 ± 12,5 µg/dL) to those reported by Waddell et al. (2001) for PRBC 
units stored properly (respectively  23 ±8 and  276 ± 56 µg/dL)  while at D28 
our ammonia concentration result much lower (343,445 ± 16,1 µg/dL in our 
study, 466 ± 30 µg/dL in the study of Waddell et al., 2001). This difference is 
probably due to the different kind of additive solution which have different 
composition, characteristics and storage times. Finally, the fact that the standard 
deviation of ammonia concentration present in our study is fairly small (between 
6 and 16) is probably due to a correct preservation of the units. In fact, the 
ammonia is a very sensitive parameter which, as highlighted by Waddell et al. 
(2001), suffers much of an improper storage. In fact, in the study conducted by 
Waddell et al. (2001) there is a large difference in ammonia concentration 
between units of PRBC stored in small refrigerator open frequently (that showed 
higher ammonia values) and PRBC stored in large blood-banking refrigerator 
that was not opened more than once a day for the entire 35 days of storage.  
Unfortunately in our study was not possible to obtain the real final ammonia 
concentration  because our kit arrives to measure a concentration of ammonia 
maximum of 470 µg/dL. 
Finally, in our study, we also evaluated the possible bacterial contamination of 
PRBC units. No PRBC unit has showed positive culture at D0, D21 and D42. 
We decided to evaluate PRBC not only at D0 and D42 but also at D21 because a 
study estimated that, at storage temperatures of blood bags ( 4 ± 2 °C), the 
quantity of bacteria capable of inducing sepsis in the recipient patient is reached 
around the nineteenth day of storage (Hess, 2004).  In the author’s knowledge 
there are no studies about bacterial contamination of canine blood units and in 
veterinary literature there is only the description of two contaminating bacteria, 
Pseudomonas fluorescens and Serratia marcescens. Both cases are reported in feline 
transfusion medicine characterized by the use of open systems to collected blood 
(Hohenhaus et al., 1997; Kessler et al., 2010).  
Despite the negative result of culture on our PRBC units we believe that is 
fundamental pay close attention to possible bacterial contamination during all 
steps of  PRBC preparation (evaluation of the donor, blood collection, 
centrifugation, preparation and storage of the bags and proper storage) and that 
the bags must be visually evaluating 3-4 times per week looking for changes in 
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color or texture (signs of probable contamination) to reduce at minimum the 
risks of contamination. 
Based on our results we can say that the blood collection, preparation and 
storage of  PRBC canine units analyzed in our study, provides a final product 
safe for the absence of bacterial contamination. 
As in other species the ammonia concentration increased steadily during storage. 
In the absence of studies regarding the effect of this alteration in subjects with 
hepatic disease we avoid transfusion with older units in these subjects. In fact 
already at D14 of storage most of the units show values of ammonia far above 
the canine normal value.  
As regards the evaluation of hematological parameters the results obtained by us 
agree mostly with what is reported in canine and human medicine. Like reported 
in man, dog and horse would be interesting to evaluate the permanence of 
transfused red blood cells in the recipient at different time of storage and to 
perform the evaluation of further parameters that characterize the quality of the 
product like potassium, glucose, pH value, entity and percentage of free 
hemoglobin, red blood cell hemolysis index entity, content of ATP and 2,3 
DPG, molecules essential for cell survival. 
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3. The safety and quality of feline whole blood units 
collected with an open system and the effect of 
storage on hematological parameters and ammonia 
concentration    
 
3.1 Abstract  
The veterinary transfusion medicine is constantly in progress but still now feline 
blood donation, collection, and conservation of whole blood and blood products 
present some problems. Feline whole blood collected with open system and 
stored in CPDA1 for 35 days at 4°C was evaluated for hematological parameters, 
ammonia concentration and sterility during the storage period. Statistical analysis 
resulted in significant increase in ammonia concentration and decrease of WBC. 
No other significant changes resulted in hematological parameters (RBC, Ht, 
MCV, RDW). No units presented bacterial contamination during storage. The 
use a standardized protocol during blood collection, preparation and storage of 
feline whole blood permit to obtain a product without microbial contamination, 
minimum changes in haematological parameters but with a very high ammonia 
concentration.  
 
3.2 Introduction 
The progress recently made in veterinary medicine, particularly in intensive care 
and emergency medicine, have increased the interest to veterinary transfusion 
medicine. There are different diseases that can require transfusion, as acute loss 
of large quantities of blood, coagulation disorders and chronic non-regenerative 
anemia (Weingart et al., 2004). In canine transfusion medicine it can used whole 
blood (WB) or  blood components: packed red blood cells (PRBC), fresh frozen 
plasma (FFP) frozen plasma (FP), platelet rich-plasma (PRP) and cryoprecipitate 
(Lucas et al., 2004). These components permit to optimize every donation from 
which can be obtain two different components and, at the same time, increase 
the effectiveness of transfusion therapy and reduced transfusion reactions caused 
by no necessary blood components. 
In feline transfusion medicine, however, is mainly used fresh whole blood or 
WB. There are different problems related to feline blood donation, collection 
and conservation of blood products: the frequently need  of anesthesia of the 
donor during blood collection, to use of open collection systems (as is not 
possible use human blood bag), the difficult to separate whole blood into its 
components due to the smaller amount of blood that constitutes the sample 
(unit of whole blood is about 50-60 mL) (Weingart et al., 2004 ). 
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The purpose of this study is to evaluate the quality of feline whole blood 
obtained with an open system, preserved with anticoagulant CPDA-1 (citrate-
phosphate-dextrose with adenine) and storage for 35 days at 4°C. Four 
parameters were chosen as indicators of the quality of the bag at the end of 
preservation: sterility, ammonia concentration and hematological parameters.  
 
3.3 Materials and methods 
All units of whole blood were obtained from owned cats and cats belongings to 
a closed colony enrolled as donors in the volunteer feline donor program of the 
Reparto Emotrasfusionale Veterinario (REV)of  University of Milan. All cats 
were healthy large cats (> 5 kg of weight), 2-8 years of age, correctly vaccinated 
with core vaccinations (feline calicivirus, herpesvirus and panleucopenia). For all 
cats blood typing (Lab test A+B, Alvedia), clinical visit and screening with 
complete blood count (CBC), chemistry panel and infectious disease test were 
performed. The test for infectious diseases were the following: feline leukemia 
virus antigen and feline immunodeficiency virus antibody (Snap FeLV/FIV 
Combo Plus Test; Idexx Laboratories, Hoofddorp, the Netherlands ) and 
Mycoplasma haemofelis on blood smear. In case of doubt or positivity for M. 
haemofelis at blood smear the result was confirmed submitting an EDTA-blood 
sample to PCR test. Cats were excluded if any retroviral or PCR test resulted 
positive or if they had hematological, biochemical or physical abnormalities.  
 
3.3.1 Donor preparation and blood collection  
All equipment is prepared and arranged prior to starting the donation procedure. 
The donation session required the participation of at least 3 people (minimum 2 
vets) – one phlebotomist, one adequately trained personnel to restrain and 
monitor the donor, as well as to assist with handling of the collection equipment 
during the donation and a third person to aspirate blood and rock the syringe 
during the collection. All cats are 12 hours fasted and required anaesthesia. Cats 
were anaesthetised with a combination of tiletamine and zolazepam (Zoletil 100; 
Virbac, Milan, Italy) at a dose of 12 mg/kg given intramuscularly in the thigh 
muscles, based on body weight.  
A 20-22 G catheter was aseptically placed into the cephalic vein for the purpose 
of administering saline solution during and after blood collection.  
Three 20 ml syringes were loaded immediately before the blood collection with 
2,3 ml of CPDA 1 taken every time by a new and closed human single collection 
bag (Terumo single blood bag, 350 ml with 49 mL di CPDA) to obtain a feline 
unit of whole blood corresponding to 53 ml of whole blood and 7 ml of 
CPDA1. 
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The area over the jugular vein was shaved and prepared aseptically with ethanol 
(ethanol 94°, ACEF S.p.a) prior to venepuncture  and the cat was put in lateral 
or sternal recumbency. 
Blood was collected with a 19G winged infusion set (butterfly) attached to the 20 
ml syringe with CPDA1 (open system) (Photo 1). The syringes were gently 
rocked during blood collection to ensure adequate mixing of blood and 
anticoagulant. Blood collection was typically completed in 5-10 minutes and vital 
signs were monitored through the procedure. Routine monitoring during and 
post anaesthesia was performed. Also the blood pressure was monitored with 
high definition oscillometry (Memo Diagnostic - High Definition Oscillometry) 
before, during and after the blood donation The protocol for the fluid therapy 
provided  subcutaneous infusion of 90 ml of physiological solution (NaCl 0.9%) 
before the blood collection and intravenous infusion of 60 ml of the same 
solution starting half way through the donation was performed. (Kohn et al., 
2012). After blood donation cat was monitored (mucous membrane colour, 
pulse rate and strength, respiratory rate)  and returned to the owners when fully 
awake.  
 
3.3.2 Blood bag units preparation 
At the end of the donation 1 ml of whole blood was put on a sterile empty test 
tube maintained at room temperature an another 1 ml in a sterile empty tube 
maintained at 4°C. The remained blood was transferred to a 150 ml storage bag 
(Teruflex Transfer Bag) (Photo 2). The whole blood was gently rocked back and 
forth to ensure adequate mixing. Using a manual tube stripper the blood 
remaining in the tubing was stripped into the bag, the bag was gently manually 
mixed and compressed to refill the tubing. This procedure was made for 3 or 4 
times to have a correct distribution of whole blood into the tube. The tubing was 
sealed with a thermal sealers (Hemoweld B-Delcon, Italy) to provides 4 aliquots 
of about 0.3 ml (tubing 5 cm long) which were used to performed tests (Photo 
3). 
 
3.3.3 Whole blood units storage  
All bags were labelled with the date, the type and volume of the product, 
identification number of the donor, blood type, collection and expiration date 
(Photo 4).  
One aliquot of whole blood was taken immediately before the storage to 
performed laboratory test at day 0 (D0). The bag was then stored in a specialized 
blood storage refrigerator (Emoteca 250, Fiocchetti, Italy) with built-in 
temperature alarm at 4°C ± 2°C. The bags was posed horizontally to reduce the 
risk of damage and to maximize oxygen diffusion in to, and carbon dioxide 
diffusion out of, the bag. To ensure a uniform distribution of the anticoagulant 
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solution and increase the viability of red blood cells the bags were manually 
massaged and gently mixed three - four times per week. During these manualities 
the bags were submitted to visual inspection of color and texture to search clot 
or fibrin (signs of possible contamination)  
 
3.3.4 Blood culture 
24 hour after the blood collection the 2 samples of blood, one maintained at 
room temperature and one at 4°C, were subjected to culture. A second aliquot of 
whole blood was taken at the expiry date (D35) to perform culture and 
laboratory test.  
The blood culture was performed using a modified and adapted standard 
microbiological procedures (Carter and Wise, 2004). The culture was made on a 
room temperature sample and a refrigerated sample at D0 and on a refrigerated 
sample at D35. The double culture at D0 had the objective to verify the presence 
of bacteria inhibited by refrigeration temperatures. An amount ranging from 200 
to 500L of blood was seeded in sterile way in a culture broth (Tryptic Soy 
Broth, TSB, Oxoid, Italy) in a 1:10 ratio. The tube was then incubated at 37 ° C 
for 24 hours; if after this period, the broth was clear, with packed red cells on the 
bottom, the tube was again incubated for 24 hours up to a maximum of 72 
hours; over this period the sample was indicated as sterile. 
On the contrary in case of turbidity of the culture medium, index of positivity, 
100  L of sample was transplant on solid medium agar-blood, which is obtained 
by adding defibrinated sheep blood to base medium Tryptic Soy Agar (TSA) 
(Microbiol, Italy). This solid culture medium allows to obtain colonies with the 
macroscopic morphology typical of the various bacterial species. Then the plate 
was incubated at 37 ° C also for 24 hours, after which it is proceeded to the 
identification of bacteria by macro-and microscopic examination (evaluation of 
macroscopic morphology and execution of the Gram stain), construction of 
simple biochemical tests and transplantation on selective and differential culture 
medium (Quinn et al., 2002; Carter et al., 2004; Poli et al., 2005; Jones, 2006). 
Also visual inspection of color and texture of all blood units was made to search 
clot or fibrin, signs of a possible contamination.   
 
3.3.5 Ammonia concentration and Hematological Parameters 
Before performing tests the tube segment was manually mixing for 1 minutes, 
after this the sample was taken with a 27 gauge needle and syringe and put in an 
eppendorf tube. The eppendor tube was gently mixed 2-3 times before measure 
ammonia with an automated tool (Ammonia Checker II model AA-4120, 
Menarini, Italy) and a special test strip (Ammonia test KIT II, Menarini, Italy). 
The remaining sample was put on a blood rocker for minimum 5 minutes before 
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performing CBC (Cell-Dyn 3500 PLUS, ABBOTT Diagnostics). The same 
procedure were made at D0 and D35.  
 
Photo 1: Collection of blood through the jugular vein using three 20 ml syringes pre loaded with 
anticoagulant CDPA-1 
 
 
 
Photo 2: Transfer of collected blood from 3 syringes into a sterile empty storage bag of 150 ml. 
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Photo 3: Units of feline whole blood at the end of the preparation. Small aliquots use to perform 
evaluation of hematological parameters, ammonia concentration and blood culture  are visible on the 
top of the bags.  
 
 
3.4 Statistical Analysis  
Data analysis was performed using a commercial statistical software (MedCalc 
Software, Mariakerke, Belgium). Data were tested for normality using the 
Shapiro-Wilk.  Minimum, maximum, mean and standard deviation (SD) of 
ammonia concentrations, RBC, WBC, Ht, MCV,  RDW  were compared using a 
Student t test. Number and percentage of contaminated bags were reported. A p 
value < 0.05 was considered statistically significant. 
Hemoglobin had not been considered in the statistical analysis because the 
automated hematology analyzer used in this study (CELL-DYN 3500 PLUS, 
Abbott Diagnostics) lyses red blood cells to determine hemoglobin 
concentration so the authors can not distinguishing among the hemoglobin 
present in the plasma and resulting from the normal in bag hemolysis and the 
hemoglobin contained inside the red blood cells. Because MCH and MCHC are 
calculated by the analyzer staring from hemoglobin values also these 2 
parameters were excluded from the statistical analyses.  
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3.5 Results 
3.5.1 Blood culture 
During the study period (year 2012) a total of 26 units of feline whole blood (53 
ml of whole blood and 7 ml of CPDA-1) were obtained and stored.  
The blood culture was performed in 26 samples at D0 and 25 samples at D35. 
 A D35 one sample was not subjected to blood culture because of insufficient 
amount of sample.   
All bags resulted without microbial contamination at the beginning (both for the 
samples stored at room temperature that for samples at refrigeration 
temperature) and at the end of preservation. No bag showed variations in color 
and no bag presented fibrin clots and macroscopically detectable. 
 
3.5.2 Ammonia concentration 
The ammonia was evaluated in 12 samples at D0 and 16 samples on D35, the 
results obtained are shown in Table 1. For technical reasons (due to 
unavailability of the instrument and reagents) in some cases it was not possible 
to determine the ammonia. It should be noted that the ammonia automated tool 
used in this study permits to evaluated a maximum ammonia value of 465 µg/dl, 
and therefore that for 15/16 samples the ammonia concentration obtained is not 
the true value, but the maximum value detected by the instrument. 
There was a statistically significant increase of ammonia concentration during the 
storage period (p < 0,0001) (Graph 1). 
 
3.5.3 Hematological parameters 
Complete blood count was performed on 25 samples at D0 and 20 samples at 
D35 of blood storage. For all samples were investigated the number of red blood 
cells (RBC), hematocrit (Hct), the red cells distribution width (RDW), the mean 
cell volume (MCV), and finally the number of white blood cells (WBC). The 
results obtained are shown in Table 2. 
The mean value of RBC, Ht and MCV decrease during the storage without a 
statistically significant difference (respectively p = 0,4; p = 0,3; p = 0,8) (Graph 
2, Graph 3, Graph 4).  
The mean RDW showed a little increase during the storage time but with no 
statistically significant (p = 0,5) (Graph 5). 
Only WBC count show a statistically difference between D0 and D35 with a 
drastic reduction of white blood cell in the storage whole blood (p < 0,0001) 
(Graph 6). 
Our analyzer (Cell-Dyn 3500 Plus, Abbott Diagnostics) permits to obtain WBC 
with 2 different method: impedance measurement (WIC) and optical counting 
(WOK ) of leukocytes. The WBC values measured with both methods have 
showed extremely different counts during all storage time. In particular WIK 
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showed an increase in WBC during the storage and WOK a decrease during 
storage. After the evaluation of some smears obtained from the same unit at D0 
and D35 we have considered more reliable the laser count (WOC). 
 
Table 1: Ammonia values obtained in feline whole blood bags at D0 and D35.  
  NH3 D0 NH3 D35 
Whole Blood Bag µg/dL 
G08/12 28,23 465 
G09/12 ND 465 
G10/12 ND 465 
G12/12 223,5 465 
G13/12 184,7 465 
G14/12 42,35 465 
G15/12 78,82 465 
G16/12 89,41 465 
G17/12 61,17 ND 
G18/12 102,35 465 
G19/12 52,94 465 
G21/12 ND 465 
G22/12 ND 451,76 
G23/12 ND 465 
G30/12 250,6 465 
G08/12 99 465 
G32/12 203 465 
Mean± SD 
118,2 464,2 
±76,6 ±3,3 
MIN –MAX 
28,3 
250,6 
451,8 
465 
p value <0,0001 
NH3 = ammonia, ND = not determined (for technical reasons). 
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Table 2: RBC, Hct, RDW, MCV and WBC obtain from 26 units of feline whole blood ad D0 and D35.  
 
 
 
 RBC 
D0 
RBC 
D 35 
HCT 
D0 
HCT 
D35 
RDW 
D0 
RDW 
D 35 
MCV 
D0 
MCV 
D 35 
WBC 
D0 
WBC 
D 35 
SACCA X 10³/µL % % fL /µL 
G07/11 7800 5320 29,3 18,1 20,8 21,9 37,6 34 10800 1480 
G08/11 7150 6190 28,9 24,6 17,4 16,9 40,4 39,8 11200 1200 
G01/12 7660 ND 32,1 ND 17,3 ND 41,9 ND 6570 ND 
G02/12 8150 ND 29,3 ND 20,4 ND 36 ND 12500 ND 
G03/12 8910 ND 35,6 ND 18,6 ND 40 ND 17300 ND 
G04/12 6760 ND 21,9 ND 23,5 ND 32,4 ND 6300 ND 
G05/12 8680 6570 36 26,4 18 17,1 41,5 40,2 6510 559 
G06/12 8450 8730 31,6 32,2 18,9 21,7 37,4 36,9 8100 833 
G07/12 9050 6660 35,8 26 17,9 17,5 39,6 39,1 6140 1020 
G08/12 9610 6320 36,2 24,8 16,1 17,2 37,7 39,2 13400 1320 
G09/12 ND 7660 ND 30,7 ND 19 ND 40,1 ND 435 
G10/12 6190 5980 23,5 22,9 18,4 18,4 38 38,4 9070 4030 
G11/12 7950 ND 35,3 ND 17,4 ND 44,4 ND 18000 ND 
G12/12 10000 7560 38,4 29,3 19,6 17,6 38,4 38,7 8720 608 
G13/12 7510 5910 29,9 23,4 18,2 17 39,8 39,5 5070 1110 
G14/12 7380 8070 27,5 29,9 18,5 18,7 37,3 37,1 7500 1340 
G15/12 8230 12000 29,8 41,8 19,4 23,9 36,2 34,7 13400 822 
G16/12 6130 6620 24,5 25,9 16 17,9 40 39,1 10400 370 
G17/12 6710 ND 27,3 ND 16,6 ND 40,7 ND 8890 ND 
G18/12 5470 ND 20,6 ND 18 ND 37,6 ND 15200 ND 
G19/12 5710 6460 21,8 25,2 15,5 17,5 38,2 39 7620 483 
G21/12 6110 6600 23,8 28,6 17,5 17,9 38,9 43,3 7980 931 
G22/12 7280 7490 26 26,6 19,3 22,1 35,7 35,5 11600 763 
G23/12 5530 5770 20,6 22,2 18,3 18,8 37,3 38,5 9710 2320 
G30/12 10700 11100 44,6 43,5 17,6 19 41,8 39,2 5010 997 
G08/12 ND 6770 ND 25,8 ND 17,5 ND 38,2 ND 209 
G32/12 6770 6590 27,5 27,7 17,5 15,9 40,7 42 3550 123 
Mean± SD 7595,6 7218,5 29,5 27,8 18,3 18,7 38,8 38,6 9621,6 1047,6 
±1423,2 ±1784,3 ±6,2 ±6,0 ±1,7 ±2,1 ±2,5 ±2,2 ±3631,3 ±860,4 
MIN - 
MAX 
5470 - 
10700 
5320 - 
12000 
20,6 - 
44,6 
18,1 - 
43,5 
15,5 - 
23,5 
15,9 - 
23,9 
32,4 - 
44,4 
34 - 
43,3 
3550 - 
18000 
123 - 
4030 
p value 0,4 0,3 0,5 0,8 <0,0001 
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Graph 1: ammonia concentration in bags of feline whole blood with CPDA1 stored for 35 days. 
Ammonia values are expressed in µg/dL.  
 
Graph 2: RBC in bags of feline blood with CPDA1 stored for 35 days (RBC x 10³/µL). 
   
Graph 3: Hematocrit in bags of feline blood with CPDA1 stored for 35 days (%). 
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Graph 4: MCV in bags of feline blood with CPDA1 stored for 35 days (fL) 
 
Graph 5: RDW in bags of feline blood with CPDA1 stored for 35 days (%) 
 
Graph 6: WBC in bags of feline blood with CPDA1 stored for 35 days (µL) 
32
34
36
38
40
42
44
46
MCV_D0 MCV_D35
15
16
17
18
19
20
21
22
23
24
RDW_D0 RDW_D35
0
2000
4000
6000
8000
10000
12000
14000
16000
18000
WBC_D0 WBC_D35
52 
 
3.6 Discussion 
All bags of feline whole blood in our study  were visually checked 2-3 times at 
week in order to highlight possible alteration of color, presence of hemolysis or 
turbidity of the plasma fraction,  presence of clots or fibrin, all signs of possible 
bacterial contamination (Kessler et al., 2010). The ocular  inspection carried out 
on our bags stored did not detect any macroscopic alteration. The bags of stored 
feline whole blood of our study were also analyzed for bacteriological research at 
D0 on a sample maintained at room temperature and on a refrigerated sample 
and also at D35 on a stored sample. All samples submitted to culture result 
negative for bacterial contamination.  
In human medicine, 1/2000 unit of blood bag collected is contaminated 
(Yomtovian et al., 2006), but fortunately, thanks to storage at low temperatures, 
many of these bacteria do not survive during storage (Hess, 2010). There are 
numerous studies in human medicine that described  the presence of bacterial 
colonies on stored blood (Black et al., 1967; Blajchman et al., 1979; D'Antonio et 
al., 2002; Sharma et al., 2004; Blajchman et al., 2005, O'Brien et al., 200). The 
bacteria involved in the contamination of human blood products are numerous, 
the main and most frequent among the Gram-positive bacteria are staphylococci, 
streptococci, Clostridium perfringens and Bacillus cereus; among Gram-negative 
bacteria are mainly represented by Yersinia enterocolitica, Serratia marcescens and 
Serratia liquefaciens (Hogman et al., 1998). 
The veterinary literature reports only the description of two contaminating 
bacteria, Pseudomonas fluorescens and Serratia marcescens, both cases are reported in 
the context of transfusion feline medicine (Hohenhaus et al., 1997; Kessler et al., 
2010). This  demonstrate that the open system use in feline blood collection is an 
important risk factor for bacterial contamination.  
We decided to analyze blood units at D0 and D35 because blood is an excellent 
microbial growth medium and the amount of bacterial colonies present at D0 
may increase during storage (Hohenhaus et al., 1997; D'Antonio et al., 2002). In 
fact analyzing the bag only on D0 the amount of bacteria present could be less 
than the detection capability of the method use for the bacteriological 
investigation (Kessler et al., 2010), and a bag can  be incorrectly labeled as 
“sterile”. It is also known that the risk of microbial contamination increases 
during the conservation and it reaches its peak in the nearest days to maturity of 
the product (Hogman et al., 1998). It is estimated that, at storage temperatures of 
blood bags, the quantity of bacteria capable of inducing sepsis in the recipient 
patient is reached around the nineteenth day of storage (Hess, 2004). 
The results of our study show that, although operating with an open system, it is 
possible to obtain a totality of blood units without bacterial contamination  both 
at the beginning that at the end of storage period.  
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This result was achieved thanks to a scrupulous collecting system and to a high  
attention to eliminate or limiting all possible sources of contamination (for 
example skin flora) (Scott, 1984; Muller et al. 2001). It is also important to 
maintain for all blood collections a standardized procedural scheme to ensure 
uniformity of results.  In fact  a study shows  that only thanks to the repeatability 
of the work we can be able to find the source of contamination (Hohenhaus et 
al., 1997). 
The literature provides conflicting data regarding the percentage of 
contamination of the blood bags (Engelfriet et al., 2000) and is even more 
difficult to get statistics in veterinary medicine because fewer studies have been 
done about it. 
For this reason is difficult to determine whether the result on bacterial 
contamination in our study really reflects the general situation or if it represents 
our reality only. 
The ammonia concentration in units of feline whole blood in our study was 
assessed on D0 few hours after blood donation and at D35. Our result detects 
that the ammonia concentration grows during the period of storage. In fact there 
is a statistically significant difference (p <0.0001) between the means of the 
samples on D0 (118 µg/dL ) and D35 (464.2 µg/dL). The values obtained in 
D35 have reached in 15/16 samples the maximum value detected by the 
instrumentation. We can therefore say that the ammonia concentration on D35 
is greater than that detected, even if it is not possible to know the exact 
magnitude of the final ammonia value. 
The scientific literature about feline medicine report few studies about ammonia 
concentration. A work of Ogilivie et al. (1985) measured the ammonia 
concentration in feline plasma stored at -20 ° C for 9 days. This study shows a 
statistically significant difference between the values measured at day 0 and at 
day 9, showing an increase of the value of 13 times. However, the different 
storage temperature, the different sample and the different time interval makes it 
difficult to make a direct comparison between the 2 studies. In addition to this 
work, there are also studies, more similar for time and mode of observation to 
our study conducted in human medicine both on whole blood and PRBC and in 
canine medicine to PRBC which results are perfectly integrated with data 
obtained from our study (Prytz et al., 1970; Waddell et al., 2001). In fact, even in 
these works, is highlighting a statistically significant difference in ammonia at the 
start and at the end of storage. 
On D0 of our study the ammonia concentration show a large SD that indicates 
the wide range of values of baseline ammonia concentration. The measurements, 
in fact, vary from a minimum of 28 µg/dl to a maximum of 251 µg/dl with a SD 
of 76.6 µg/dl. This result has also been seen in studies of human medicine (Prytz 
et al., 1970) and demonstrate how this parameter is sensitive to any variation in 
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sample preparation. Furthermore this variability of baseline ammonia to D0 
could reflect a different concentration of ammonia in the blood of the donor, 
that evaluation is not performed in our study. 
The study of Waddell et al. (2001) on the evaluation of ammonia in canine unit 
of PRBC performs measurements on days 0, 7, 14, 21, 28 and 35 of storage 
showing a linear correlation between increased concentration of ammonia and 
storage time. The above cited work of canine medicine has been carried out on 
samples of PRBC, while the samples of our study come from whole blood. 
However it is possible a comparison between these two studies since it has been 
demonstrated that the increase of ammonia, which takes place in whole blood, 
occurs almost entirely by the red blood cells (Conn, 1966). In fact, similar results 
are obtained by measuring the concentration of ammonia in human whole blood 
and PRBC. (Prytz et al., 1970; Waddell et al., 2001). 
All whole blood units of our study were evaluated at the beginning and at the 
end of the storage for the following blood parameters: RBC, Ht, MCV, RDW, 
WBC. The statistical analyzes performed on the considered parameters showed a 
substantial stability of the parameters during the storage in anticoagulant CPDA-
1 for 35 days. 
The red cell distribution width (RDW) is the only parameter to be increased, 
slightly, during storage. RDW rises from 18.3% at D0 to 18.7% to D35. This 
data shows a slight increase of the variability in the size of red blood cells. These 
results are similar to what is shown in a study of Niinistö et al. (2008) where no 
statistically significant difference was detected in the cell count at D0 and D35 in 
equine red blood cells stored in SAG-Mannitol. 
The analysis of white blood cells at day 0 and on day 35 instead shows a marked 
decrease in the number. Leukocytes pass from a mean value of 9621.6/µL at D0  
to 1047.6/µL at the end of storage, with a highly statistically significant 
difference (p <0.0001). The analysis of blood parameters has rarely reported in 
the scientific literature, and to the authors knowledge there are no studies about 
feline species. However, it is possible to draw some conclusions from human 
medicine. Interesting is the comparison with the work of human medicine of 
Garritsen et al. (2003) in which were analyzed the differences of blood 
parameters in units of packed cells obtained from placental blood after 35 days 
of storage in SAG-Mannitol. From this study there is a substantial stability in 
RBC but a statistically significant difference between Ht at D0 and D35 (p 
<0.05) (Garritsen et al. 2003). The difference with our study may be due both by 
the different preservative solution and the diverse species.  
Red blood cell indices are studied also by Turner et al. in 1987. In this study 
human packed red blood cells shows a stability during the 42 days of observation 
with regard to the cell volume and the average concentration of hemoglobin; 
however, the authors attribute this result not so much to a real cell stability 
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during storage but to a "masking" effect a of CPDA-1 solution. In fact, if the 
RBC stored for more than 21 days are introduced into a solution of fresh plasma 
at 37 ° C, situation that better mimics the placing in the circulation for 24 hours, 
it can notice a change in cells characteristics with a statistically significant 
decrease in cell volume and a significant increase of the average concentration of 
hemoglobin (Turner et al., 1987). The statistically significant decrease of WBC 
occurred during the storage reflects the results obtained in other studies. From 
the literature it emerges that in feline species the amount of WBC in stored 
blood is significantly decreased (p <0.01) already after the first 72 hours of 
storage (Grenn et al, 1976) and in human medicine after 35 days of storage the 
WBC comes to be equal to 0 (Garritsen et al, 2003). These results, however, do 
not come unexpected. It is in fact known that the very short duration of life of 
granulocytes does not allow the storage and transfusion of this product (Kohn et 
al., 2012). 
Analysis of the literature and the results obtained in our study probably reveal a 
good stability during storage of red blood cells, even if is not clear if this stability 
is real or only apparent. Much of this stability is probably attributable to the type 
of anticoagulant used,  CPDA-1. This preservative and anticoagulant solution 
contains dextrose which is a substrate for glycolysis in red blood cells, citrate 
which prevents coagulation by inhibiting the calcium-dependent coagulation 
cascade, and phosphate which results in a high production of ATP during 
storage. Adenine finally improves ATP synthesis of red blood cells. In fact 
erythrocytes can not synthesize adenine, but they can use it together with glucose 
to form ATP and AMP. For all these features the CPDA-1 is the anticoagulant-
preservative of choice even in feline transfusion medicine (Kohn et al., 2012). 
In conclusion the open system used in this study to collect feline whole blood 
with CPDA1 permits to stored feline blood for 35 days without bacterial 
contamination, with few changes of hematological parameters but with an high 
concentration of ammonia.  
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4. Preliminary Evaluation on the Stability of Protein 
in Bovine Fresh Frozen Plasma 
 
4.1 Abstract 
The aim of this study were to evaluating preliminary stability of glucose, urea, 
total protein and protein fractions in bovine fresh frozen plasma (FFP). Blood 
was collected into human sterile double-pack blood collection system containing 
citrate-phosphate-dextrose-adenine (CPDA) and after centrifugation the plasma 
units were stored within 8 hours from blood collection at – 19°C obtaining FFP. 
The analysis of biochemical parameters were performed on fresh plasma after 
centrifugation of whole blood unit and on thawed FFP after 1 and 6 months of 
storage. Pre and post storage results were compared using a one way repeated 
measures ANOVA. Seven FFP were obtained from 7 different whole blood 
units. There was no significant changes in the concentrations of glucose, urea, 
total protein and protein fraction during the entire period of storage. This 
preliminary study showed that during  6 months of storage no significant 
changes were appeared in the evaluate biochemical parameters in bovine FFP.    
 
 
The development of blood banking and component processing in veterinary 
medicine has resulted in more frequent use of blood components like Packed 
Red Blood Cells (PRBC) and Fresh Frozen Plasma (FFP).  In particular plasma 
is most commonly used for the proteins it contains, such as albumin, 
immunoglobulins, and hemostatic proteins particularly  in human (Benjamin et 
al., 2012) and canine medicine (Gibson et al., 2012).  FFP is indicated for use in 
animal with acquired or inherited coagulopathies (inherited factor deficiencies, 
vitamin K deficiency or antagonism, disseminated intravascular coagulation, 
severe liver disease), with hypoproteinemia (Gibson et al., 2012) or to give 
passive transfer of immunoglobulin (Prettie et al., 2004, Green, 2012)   
Even if bovine blood and blood products are often used for the production of 
biopharmaceuticals (e.g. Vaccines) sometimes also in bovine medicine is 
necessary for the practitioner use whole blood or blood product.  In literature 
are reported single cases in which fresh whole blood transfusion has been used 
for particular disease like a bovine neonatal pancytopenia  (Bernier Gosselin et 
al., 201) or idiopathic immune-mediated anemia (Lallemand et al., 2006). Others 
studies report the use of bovine plasma or hyperimmune bovine plasma in 
newborn calves for the management of  failure of passive transfer (Turgut et al., 
1996, Selim et al., 1995).  
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In bovine species blood collection and donation can be difficult to perform in 
practice, are time-consuming, expensive, and stressful to the animal (Hunt et al., 
1999) but in contrast to the whole blood from which it is derived, plasma can be 
stored frozen, making it a convenient product to keep in most veterinary 
hospitals or veterinary blood bank. To be labeled as “FFP,” the plasma must be 
placed in a -18°C or lower freezer within 6 to 8 hours of phlebotomy (Benjamin 
et al., 2012) . Maximum storage times for animals  have been adapted from 
studies on human plasma. Based on it FFP maintains for 1 year all the 
components of a fresh plasma (albumin, globulin, hemostatic factors) even if a 
canine study (Wardrop et al., 2001) report statistically significant changes in 
some coagulation factor during the storage.  
The aim of this study is to assess the stability of glucose, urea, total protein, 
albumin and globulins in bovine FFP obtained from centrifugation of whole 
blood in CPDA and stored within 6-8 hours from phlebotomy at -19°C.  
The plasma was obtained at the Reparto Emotrasfusionale Veterinario (REV) of 
Faculty of Milan from bovine whole blood collected using human sterile double-
pack blood collection system (CPDA double bag, 450 ml, Grifols, Barcelona, 
Spain)  To obtain FFP all samples were submitted with 8 hours of blood 
collection to centrifugation and separation using a blood centrifuge (Rotixa 50 
RS – Hettich, Germany).  
The blood centrifuge was set at a temperature of 4° C, 3500 RPM with initial 
acceleration (run up 9) and free deceleration (run down 0) for 15 minute and it 
had permitted to obtain a clear bovine plasma without red blood cell 
contamination.   
Plasma was separated from RBCs using a manual plasma extractor (Separation 
stand Teruflex ACS-201). When the plasma had been extract almost completely 
the tubing just above the plasma bag was clamped. The satellite bag containing 
plasma and the anticoagulant was separated from the other bag (containing 
mainly red blood cells) with the use of thermal sealer. The tubing was sealed with 
the thermal sealers to provides 4  aliquots of about 2 ml.  
One aliquot of fresh plasma was taken immediately before the storage to 
performed all tests. Fresh plasma was submitted to determination of glucose, 
urea, total protein (TP) and electrophoretic separation using agarose gel (AGE) 
to obtain the protein fractions and albumin. The glucose was quantified with a 
enzymatic colorimetric determination (GOP-POD-PAP), urea with UV kinetic 
method,  TP with a spectrophotometric determination using a Biuret Method on 
an automatic system for blood chemistry (Cobas Mira Classics Roche). The 
protein fractions were evaluated in concentration (g/dl) and also for percentage 
(determination of peak-area of the electrophoresis scanning pattern). Also 
albumin to globulin ratio (A/G) was calculated. AGE of plasma samples was 
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performed using a semi-automated agarose gel electrophoresis system (Hydrasis, 
Sebia PN 1210, Issy-les-Molineaux, France). 
The bags and the aliquots of fresh plasma were immediately stored in a 
specialized blood storage freezer with built-in temperature alarm at -19°C. to 
obtain FFP. After 1 and 6 months of storage one aliquot of FFP was thawed at 
room temperature  and submitted to the evaluation of the same parameters 
evaluated on the fresh aliquot at day 0.  
Data analysis was performed using a commercial statistical software (MedCalc 
Software, Mariakerke, Belgium). Mean glucose, urea, TP, AGE and A/G at each 
sampling point were compared using a one way repeated measures ANOVA. 
Test significance was set at P < 0.05 
A total of seven fresh frozen plasma units obtain from 7 different whole blood 
units were subjected to evaluation of glucose, urea and proteins at D0, before 
storage, and after 1 and 6 months of storage.   
The values registered in each sample for all evaluated parameters, the mean 
values and standard deviation of pre- and post-storage samples are reported in 
table 1 and table 2. 
The ANOVA analysis of all parameters evaluated do not show statistically 
significant modification during the storage period (all p > 0.05).   
The results of this study represent a preliminary findings in the stability of 
plasma components in bovine FFP. Data obtain on bovine FFP in a 6 months 
period storage seems to demonstrate that glucose, urea and plasma proteins are 
stable during storage at -19°C.  
Stability of serum and plasma protein after storage has been reported in the 
veterinary literature (Thorensen et al.., 1995, Reynolds et al., 2006, Cray et al., 
2009, Yaxley et al., 2010) while significant differences between pre- and post-
storage values has been noted in canine FFP for coagulation factors VIII, IX, 
and X, and vWf (Wardrop et al., 2001). Based on our preliminary results, it can 
be assumed that stored bovine FFP could be used in bovine medicine for 
example in case of necessity for the transfer of passive immunity in calves that 
have not taken properly colostrum. 
The present study does have some limitations. The first is the small number of 
samples evaluated, the second the short evaluated storage time. Moreover our 
study has evaluated only glucose, urea, total protein and protein fraction without 
evaluating the others important constituents of plasma like coagulant factors.  
However, additional studies are needed to gain more information about the 
stability of bovine FFP evaluating longer freeze periods and other plasmatic 
factors.   
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Table 1: Total protein concentration (biuret method), concentration and percentage of albumin, α1, α2, β1, β2, and γ globulin fractions (agarose gel electrophoresis) and 
calculated albumin/globulin (A/G) ratios in fresh plasma samples (D0) and fresh frozen plasma samples (D1 and D6) stored and then thawed from 7 different bovine 
FFP. 
 
 
 
 
 
 
 
 
 
 
Sample TP  TP TP Alb 
g/dl 
Alb 
g/dl 
Alb 
g/l 
Alb 
EF 
g/dl 
Alb 
EF 
g/dl 
Alb 
EF 
g/dl 
α  1 
EF 
g/dl 
α  1 
EF 
g/dl 
α  1 
EF 
g/dl 
α  2 
EF 
g/dl 
α  2 
EF 
g/dl 
α  2 
EF 
g/dl 
β 1 
EF 
g/dl 
β 1 
EF 
g/dl 
β 1 
EF 
g/dl 
β 2 
EF 
g/dl 
β 2 
EF 
g/dl 
β 2 
EF 
g/dl 
γ  
EF 
g/dl   
γ  EF 
g/dl   
γ  EF 
g/dl   
 D0 
fresh 
D1 
frozen 
D6 
frozen 
D0 
fresh 
D1 
frozen 
D6 
frozen 
D0 
fresh 
D1 
frozen 
D6 
frozen 
D0 
fresh 
D1 
frozen 
D6 
frozen 
D0 
fresh 
D1 
frozen 
D6 
frozen 
D0 
fresh 
D1 
frozen 
D6 
frozen 
D0 
fresh 
D1 
frozen 
D6 
frozen 
D0 
fresh 
D1 
frozen 
D6 
frozen 
1 7,5 8 8,8 2,9 3,2 2,9 2,84 2,8 3,23 0,27 0,31 0,33 0,41 0,44 0,5 0,28 0,3 0,34 0,44 0,5 0,53 3,27 3,66 3,86 
2 7,4 7,8 8,1 3,3 3,3 3,1 3,13 3,16 3,39 0,16 0,2 0,28 0,33 0,49 0,37 0,26 0,32 0,3 0,51 0,64 0,57 3,02 2,99 3,19 
3 7,5 8,6 7,6 3,5 3,5 3,2 3,18 3,72 3,15 0,25 0,29 0,24 0,37 0,33 0,34 0,26 0,28 0,28 0,53 0,65 0,62 2,92 3,4 2,97 
4 7 7,2 6,7 3,5 3,5 3,3 2,78 3,82 2,97 0,41 0,35 0,25 0,58 0,34 0,68 0,32 0,32 0,58 1,02 0,62 0,81 1,9 2,46 1,4 
5 7,2 7,9 7,5 3,5 3,6 3,7 3,28 3,89 3,39 0,27 0,28 0,29 0,37 0,31 0,68 0,28 0,29 0,67 0,55 0,29 0,98 2,45 2,54 1,5 
6 6,9 6,7 7,1 3,4 3,5 3,5 3,06 3,26 3,29 0,27 0,26 0,22 0,36 0,3 0,37 0,28 0,27 0,26 0,55 0,5 0,56 2,39 2,3 2,4 
7 7 6,7 6,8 2,8 2,8 3 2,59 2,59 2,45 0,27 0,25 0,24 0,36 0,32 0,32 0,27 0,25 0,22 0,59 0,6 0,49 2,93 2,7 3,08 
Mean  7,21 7,56 7,51 3,27 3,34 3,24 2,98 3,32 3,12 0,27 0,27 0,26 0,4 0,36 0,47 0,28 0,29 0,38 0,6 0,54 0,65 2,7 2,86 2,63 
SD 0.1 0,27 0,28 0,11 0,10 0,11 0,1 0,2 0,12 0,028 0,018 0,014 0,03 0,03 0,06 0,01 0,01 0,1 0,08 0,05 0,07 0,18 0,19 0,34 
Sample Alb 
% 
EF 
Alb % 
EF 
Alb % 
EF  
α  1 
% 
EF 
α  1 
% EF 
α  1 
% EF 
α  2 
% EF 
α  2 
% EF 
α  2 
% EF 
β 1 
% 
EF 
β 1 
% EF 
β 1 
% EF 
β 2 
% 
EF 
β 2 
% EF 
β 2 
% EF 
γ 
% EF    
γ 
% EF     
γ 
% EF    
A/G A/G A/G 
 D0 D1 D6 D0 D1 D6 D0 D1 D6 D0 D1 D6 D0 D1 D6 D0 D1 D6 D0 D1 D6 
 fresh frozen frozen fresh frozen frozen Fresh frozen frozen fresh frozen frozen fresh frozen frozen fresh Frozen frozen fresh frozen frozen 
1 37,9 35 36,7 3,6 3,9 3,8 5,4 5,5 5,7 3,7 3,7 3,9 5,8 6,2 6 43,6 45,7 43,9 0,61 0,54 0,58 
2 42,2 40,5 41,8 2,1 2,6 3,5 4,5 6,3 4,6 3,5 4,1 3,7 6,9 8,2 7 40,8 38,3 39,4 0,73 0,68 0,72 
3 42,4 43,2 41,5 3,3 3,4 3,1 4,9 3,8 4,5 3,5 3,3 3,7 7 7,5 8,1 38,9 38,8 39,1 0,74 0,76 0,71 
4 39,7 48,3 44,3 5,8 4,4 3,8 8,3 4,3 10,2 4,6 4 8,7 14,5 7,9 12,1 27,1 31,1 20,9 0,66 0,93 0,8 
5 45,5 49,2 45,2 3,8 3,5 3,8 5,2 3,9 9,1 3,9 3,7 8,9 7,6 7,5 13 34 32,2 20 0,83 0,97 0,82 
6 44,4 47,3 46,4 3,9 3,7 3,1 5,2 4,4 5,2 4 3,9 3,6 7,9 7,3 7,9 34,6 33,4 33,8 0,8 0,9 0,87 
7 37 38,6 36 3,9 3,7 3,5 5,1 4,8 4,7 3,8 3,7 3,3 8,4 8,9 7,2 41,8 40,3 45,3 0,59 0,63 0,56 
Mean 41,3 43,16 41,7 3,77 3,6 3,51 5,51 4,71 6,29 3,86 3,77 5,11 8,3 7,64 8,76 37,26 37,11 34,63 0,71 0,77 0,72 
SD 1,21 2 1,53 1,1 0,55 
 
0,31 0,48 0,34 0,89 0,14 0,1 0,95 1,1 0,32 1 2,16 1,96 3,92 0,03 0,06 0,04 
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Table 2: Glucose and urea concentration in fresh plasma samples (D0) and fresh frozen plasma 
samples (D1 and D6) stored and then thawed from 7 different bovine FFP. 
 
Sample Glu Glu Glu  Urea  Urea  Urea  
 D0 fresh D1 frozen D6 frozen D0 fresh D1 frozen D6 frozen 
1 339 455 430 30 32 28 
2 645 535 585 39 42 39 
3 253 430 465 31 28 26 
4 860 495 445 23 20 22 
5 525 445 510 32 25 23 
6 525 510 580 25 25 25 
7 550 440 550 24 22 25 
Mean  528.1429 472.8571 509.2857 29.1429 27.7143 26.8571 
SD 74.9223 15.2307 24.2857 2.1317 2.8006 2.1539 
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5. Foreword: No-Transfusion blood components 
and Platelet-Rich Plasma 
 
The use of non-transfusion blood components starts in human medicine in the 
1998 with the first publication of Marx at al. about the use of platelet 
concentrate (also called platelet rich plasma) in odontoiatric medicine. In the 
years a lot of production methods and different application are been proposed in 
various spheres of Medicine and Surgery.  
The most important non-transfusion blood component is the Platelet Rich 
Plasma (PRP).  
PRP  is an autologous concentration of “human” platelets in a small volume of 
plasma. Because it is a concentration of platelets, it is also a concentration of the 
7 fundamental protein growth factors (GF) proves to be actively secreted by 
platelets to initiate all wound healing. These GF include the 3 isomeres of 
platelet-derives growth factors (PDGFαα, PDGFββ, PDGFαβ),  2 of the 
numerous transforming growth factors β (TGFβ1, TGFβ2), vascular endothelial 
growth factor and epithelial growth factor. Because these platelets are 
concentrated in a small amount of plasma it also contains extra-platelets 
component that also contribute to regeneration. In particular fibrin, fibronectin 
and vitronection, proteins know to act as cell adhesion molecules for 
osteoconduction and as a matrix for bone, connective tissue and epithelial 
migration (Marx et al., 2004).  
For these reasons the rational for the therapeutic use of platelet is to make 
platelet-derived factors locally available for tissue to be healed, to induce or to 
accelerate the healing process (Mazzucco et al., 2009). 
For definition platelet concentration in PRP is above baseline whole blood 
platelet concentration (200000 platelet/µL in human medicine). Platelets are 
natural providers of platelet derived factor therefore PRP is a concentration with 
the “right” factors in the “right” proportions necessary for the healing process. 
The human arbitrary target of platelet concentration of 800000-1000000 
platelets/ µL that is three to six folds platelet concentration in whole blood has 
been proved as clinically effective by different studies, both in vitro that in vivo 
(Marx et al., 2004, Mazzucco et al., 2009). Because most individuals have a 
baseline blood platelet count of 200000 ±75000/µL a platelet count of 1 
million/µL as measured in the standard 6 ml aliquot has become the human 
benchmark for “therapeutic PRP” (Marx et al., 2004).  
The SIMTI (Società Italiana di Medicina trasfusionale e Immunoematologia) 
reported in the “Raccomandazioni SIMTI sugli emocomponenti per uso non 
trasfusionale” that PRP has a specific platelet concentration in a variable volume 
of plasma depending from method of production and use. For the SIMTI for 
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definition PRP contain 1 million platelet/µL ± 20% while the concentration of 
red and white blood cells depending to the preparation method. 
Studies have shown that an "excess" of platelet concentration does not 
necessarily determine a greater cellular response but paradoxically an inhibitory 
effect (Weibrich et al., 2004). 
The technique of preparation of PRP can be divided into four phases: collection, 
adding anticoagulant, centrifugation and product activation. 
The original technique of Marx et al. (1998) included the presence of specialized 
technicians, a blood collection of 400-500 ml in CPD performed by central 
venous catheter, a cell separator (type Eletromedics 500 of Medtronics) that, 
using a gradient of density collects and concentrates platelets during surgery. 
Such machine by 2 centrifugations allowed to obtain platelet-poor plasma (PPP, 
subsequently reinfused to the patient), platelet rich plasma (PRP) corresponding 
to the intermediate layer rich in platelets and white blood cells and a layer of red 
blood cells (packed red blood cells, PRBC, subsequently reinfused into the 
patient). Marx has also observed that the upper layer of the PRBC band (1-3 
mm) contains the youngest and largest platelets. So in PRP the first mm of the 
erythrocyte fraction has started to be include. Then considering the difficulties 
and risks associated with a so great blood collection the original technique has 
been modified (maintaining the principles of sedimentation and division of 
whole blood in PPP, PRP and PRBC) until to obtain PRP starting to a smaller 
whole blood quantitative (5-40ml) (Pacifici et al., 2002, Graziani et al., 2007).  
Actually the PRP can be prepared from blood donation using a specific blood 
collection system, from apheresis, from blood sample using a specific device 
(commercial kit) or using a manual procedure (home made).  Several 
commercially available methods to obtained PRP concentrate are currently used 
in the clinical setting and there are many types of kits, centrifuges, and vials 
available.  
There is still no universally accepted protocol for the production of PRP 
(Graziani et al., 2007). In literature are reported several discrepancies regarding 
not only the speed but also the number of centrifugations (1 or 2). 
Various kinds of anticoagulant are use in PRP preparation: heparin, citrate, acid 
citrate dextrose (ACD), citrate-theophylline-adenosine-dipyridamole (CTAD) 
(Lei et al., 2009). It is important to seek an appropriate anticoagulant to avoid 
spontaneous activation in samples, in fact if platelets are activated during the 
PRP production process, growth factors in platelets will be released into plasma 
most of which is discarded during PRP preparation, which consequently 
decreases the efficacy of PRP when applied (Lei et al., 2009). A recent study (Lei 
et al., 2009) showed that ACD and CTDA, compared with heparin and citrate, 
maintained platelet integrity for a longer time, reduced platelet spontaneous 
activation, increase the amount of growth factor released from PRP.  
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Initially the PRP is presented in liquid form and for some kind of utility, such as 
orthopedics or dentistry, must be activated to produce platelet degranulation and 
clot formation. The substance used in activation are bovine thrombin (not 
present in Italy and associated with the formation of antibodies against factors 
V, XI and antithrombin), autologous thrombin (obtained during the same phases 
of centrifugation for the production of PRP), recombinant thrombin or calcium 
(Graziani et al., 2007).  
The application of PRP (often PRP gel) covers many clinical settings including 
skin, bone, dental care, maxillofacial surgery, diabetic foot and leg, vascular and 
cardiac surgery, tympanic lesions, ocular and corneal lesions, nerve lesions, spinal 
fusion, burns, aesthetic surgery and lifting (Borzini et al., 2007).  
The use of PRP has been investigated in several studies, the majority reports 
success in promoting regeneration while others found no additional benefit 
(Everts et al., 2006, Redler et al., 2011, Borzini et al., 2007, Sampson et al., 2008). 
Therefore the clinical usefulness of PRP remains controversial (Graziani et al., 
2006). In human medicine among hundreds of published papers about the 
clinical use of platelet derivates, very few belong to the class of the prospective 
randomized clinical trials or to the category of retrospective clinical trials. The 
great majority belongs to the category of the case report or to that of the pilot 
study (Borzini et al., 2007).  The methods of preparation of PRP and 
consequently the concentration of growth factors that are achieved are variables 
and that may explain the different clinical results that are obtained (Graziani et 
al., 2006). In particular it is still uncertain which concentration of PRP are 
optimal in promoting enhanced wound healing and regeneration. (Graziani et al., 
2006).  
The extreme heterogeneity of clinical protocols presents in the literature and 
associates with discordant results have contributed to the confusion in the 
scientific community with the lack of a unanimous opinion easily interpretable 
(Marx et al, 2004, Freymiller et al, 2004, Redler et al, 2011,). Moreover, the 
absence of a unique protocol of preparation has created concerns about the 
validity of all the methods proposed. 
Even if the platelet concentration is an important factor in the definition on PRP 
the platelet growth factor content is quite variable among individuals and it is 
not necessarily proportional to the platelet count.  Activation and release of 
growth factor also occur during platelet processing. Hence the sole platelet count 
cannot be predictive of the growth factor content in individual PRP preparation 
(Mazzuco et al., 2009).   Some authors reported a correlation between such 
parameters (Epply et al., 2004) some other did not (Weibrich et al, 2002). In 
theory several factors might contribute to this lack of correlation: manipulation-
induced platelets stress, variable susceptibility of platelets to stress, and 
microaggregates affecting an accurate platelet count. Furthermore, it cannot be 
72 
 
excluded that growth factor-absorbing proteins (fibrin monomers, 
thrombospondin and other proteins release from platelet during high speed 
centrifugation phase) might affect both platelet count and growth factor 
measurement (Mazzucco et al., 2009).  
Platelets are extremely sensitive to any kind of process-induces stress, from 
blood collection to PRP gel production. Thus the amount of platelet derived 
growth factor available at the end of the manipulation process depend on 
cumulative effects over platelets starting to phlebotomy and ending with gel 
formation (Mazzucco et al., 2009). 
    
Pets (especially laboratory rats, rabbits and dogs) have been involved in a 
number of experimental studies aimed at providing models for human medicine 
(Table 1 and 2).  In some of these studies, platelet growth factors have proved 
capable of promoting the healing of different tissues (Kim et al., 2002, You et al., 
2007, Rai et al., 2007) but not in others (Jensen et al., 2004, Casati et al., 2007, 
Rabillard et al., 2009). 
In veterinary medicine some studies have been conducted to study the potential 
therapeutic effects of PRP in wound healing and in the repair lesions at tendons 
and ligaments of the horse (De Rossi et al., 2009; Torricelli et al., 2011) (Table 
3).  
The results obtained were encouraging, even if carried out on a limited number 
of subjects. 
With regard to the studies carried out on dog most have been performed to 
study a model for humans (Table 1). One study (Kim et al., 2009) reported the 
successful healing of a single chronic skin lesion unresponsive to standard 
therapy. Two other studies (Rabillard et al., 2009, Souza et al., 2012) reported the 
application of PRP for the treatment of critical size ulnar gap and a radial gap 
ostectomy with different results.  
Finally in veterinary literature there are only 2 studies (Ferraz et al., 2007, Silva et 
al, 2012) (Table 1) that attempt to standardize the method for obtaining the PRP 
autologous, so as to define a method unambiguous and reproducible, since there 
are no guidelines reliable for the production of a PRP effective. Often for the 
production of PRP in animals home made methods are used because of rapid 
implementation and low cost. These methods differ greatly in amount of blood 
used, speed, number and time of centrifugation, inclusion or not of the buffy 
coat and platelet concentration reached (Table 1). Moreover the methods of 
production are not explained carefully thus making it very difficult a possible 
reproduction. 
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Table 1: Articles relating to canine PRP prepared with home made methods (Articles with positive outcome are highlighted in green, Articles with negative outcome are 
highlighted in red) 
 
Author Journal Whole blood  
(ml) and 
anticoagulant 
Subjects 
(n°) 
Centrifugation 
(n°) 
Speed 1° 
centrifugation 
Speed 2° 
centrifugation 
Platelet 
concentration 
in PRP 
Amount of 
PRP 
obtained 
(ml) 
Conclusion 
Kim et 
al., 2002 
J Oral 
Maxillofac 
Surg 
 
 
10 ml divided 
in 2 tubes 
(5ml) 
containing 
10% of 
trisodium 
citrate 
10 2 1000 rpm for 
10’ at room 
temperature 
1 mL of the 
PPGF from 
each 5-mL 
tube was 
discarded. 
The remaining 
plasma was 
collected and 
centrifuged 
at 1500 rpm 
for 10’. 
1735000/mm3  
(range of 
1520000 to 
2005000/mm3,  
increase of 
392%). 
 “These results suggested 
that bone defects around 
titanium implants can be 
treated 
successfully with DBP and 
that PRP may improve 
bone formation.” 
Choi et 
al., 2004 
Int. J. Oral 
Maxillofac. 
Surg 
60 ml 10 2 2400 rpm for 
10’ 
3600 rpm for 
15’ 
124.2 ± 24.3 x 
10⁴/µL 
 “The results showed that 
the viability and 
proliferation of alveolar 
bone cells were suppressed 
by high PRP 
concentrations, but were 
stimulated by low PRP 
concentrations (1–5%). 
These in vitro results 
support the view that 
variations in the PRP 
concentrations might 
influence the bone 
formation within the PRP-
treated bone grafts.” 
Jensen et 
al, 2004 
Journal of 
Orthopaedic 
Research 
9 ml in EDTA 
* 12 tubes 
8 1 4000 rpm for 
20’ 
(it considered 
PRP the buffy 
coat and the 
adiacent 1 mm 
- 1884000/µL, 
mean increase 
670% 
Approximately 
0.6 ml for 
each 9 ml test 
tube. PRP 
from all 12 
samples were 
“We found no significant 
effect of PRP alone ore 
mixed with bone allograft 
on implant fixation or bone 
formation.” 
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of PPP and 
erythrocytes 
pooled 
Casati et 
al., 2007 
Int. J. Oral 
Maxillofac. 
Surg. 
Three 5 ml 
tubes with 0.5 
ml of sodium 
citrate 
10 2 1200 rpm for 
10’ 
1200 rpm for 
15’ 
460350 /µL 
(320%) 
 “it was concluded that 
platelet-rich plasma alone 
did not enhance bone 
regeneration for peri-
implant defects” 
Tae-Min 
You et al, 
2007 
Oral Surg 
Oral Med 
Oral Pathol 
Oral 
Radiol 
Endod 
20 ml 6 2 2400 rpm for 
10’ 
3600 rpm for 
15’ 
1380000/ µL 
(range: 
1010000 to 
2230000). 
 “when PRP is used as an 
adjunct to Bio-Oss in the 
repair of bone defects 
adjacent 
to titanium dental implants, 
PRP may decrease 
periimplant bone healing.” 
Rai et al, 
2007 
J Oral 
Maxxillofac 
Surg 
10 ml of 
heparinized 
blood 
8 2 2400rpm for 
10’ 
(PRP and PPP 
portions again 
centrifuged) 
3600rpm for 
15’ 
485 x 10³ ± 
110/µL 
1.3-1.4 ml “This pilot sudy suggest the 
efficacy of PCL-TCP 
scaffolds together with PRP 
from the treatment of 
critical-sized defects of the 
canine mandible. “ 
Ferraz et 
al., 2007 
Braz. J. vet. 
Res. anim. 
Sci., São 
Paulo, 
10 ml  
In sodium 
citrate  
15 2 800rpm for 10’ 1300 rpm for 
10’ 
492000/µL 
(183%) 
  
    2 800rpm for 10’ 1600 rpm for 
10’ 
542583.3/ µL 
(210%) 
 1) “the best technique 
for the preparation 
of the platelet 
rich plasma in dogs consists 
of the previous 
centrifugation of the blood 
at 800rpm for 
ten minutes, and then the 
plasma is separated and 
submitted to a second 
centrifugation of 1600rpm 
for 10 minutes, and the 
poor plasma is separated 
and 
discharged.” 
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    2 800rpm for 10’ 3200 rpm for 
10’ 
615000/ µL 
(222%) 
 2) “concentration 
obtained at 
3200rpm, in relation to the 
plasma, but it 
should be noted that all the 
samples prepared 
by this technique showed 
medium to severe 
platelet damage, and Marx 5 
inferred the 
process for the obtention of 
PRP should 
not cause harm to the 
platelets 
Li et al. 
2009 
J Oral 
Maxillofac 
Surg 
2 tubes (30ml) 
+ 4,2 ml ACD  
24 2 2000rpm for 
15’ a 4°C 
4000rpm for 
10’ a 4 °C 
1.1*106/ µL, 
(roughly 
6 times greater 
than normal 
whole blood) 
~  1 ml “ The PRP and blood 
vessels in the latissimus 
dorsi muscle could 
cooperatively promote 
osteogenesis and 
vascularization in tissue-
engineered bone” 
Kim et al 
2009. 
Vet 
Dermatol 
8 ml in citrate 
tube 
1 2 629g for 10’ 1233g for 15’ 1.0-1.2*106/ 
µL (6 times 
normal whole 
blood) 
~1 ml “This case report suggests 
that autologous PRP may 
be beneficial in the 
management of large skin 
defects or in delayed wound 
healing.” 
Rabillard 
et al, 2009 
Vet Comp 
Orthop 
Traumatol 
- 6 2 350 g for 20’ a 
4°C 
600 g for 15’ a 
4°C 
a three- to six-
fold increase of 
platelet 
concentration 
 
 
 “In this canine model 
employing a critical size 
ulnar gap, the combination 
of CaP granules and PRP 
did not effectively promote 
bone regeneration.” 
Shayesteh 
Y.S. et al 
2010 
Journal 
Compilation 
40 ml 12 2 2400 rpm for 
10’ 
(PRP and PPP 
portion again 
centrifuged)  
3600 rpm for 
15’ 
2,070.78 x 
10³/µL 
Pellet 
resuspended 
in 1 ml of 
residual 
plasma 
“The addition of PRP to 
palatal mucosal wound sites 
did not accelerate wound 
healing” 
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Sardari et 
al, 2011 
Comp Clin 
Pathol 
40 ml in 
ACD-A 
5 2 120g for 5’ 
(about 50% of 
plasma fraction 
adjacent to 
buffy coat 
subjected to 2° 
centrifugation) 
280g for 5’ About 
800.000/µL 
1.5 ml “The results of the present 
study demonstrated that 
PRP did not have 
significant effects to 
promote cutaneous 
regeneration and wound 
healing in dogs treated with 
dexamethasone at last 16 
days after last injection. “ 
Zhu et al, 
2012 
J Endod 20 ml + 3 ml 
sodium citrate 
4 2 200 g for 10’ 
(no inclusion 
of white and 
red blood cells) 
360g for 10’ > 1200000/µL.  “In the present study, we 
found that PRP alone or 
the combination of PRP 
and DPSCs did not 
enhance the regeneration of 
pulp-like tissues.” 
Silva et 
al. 2012 
BMC 
Veterinary 
Research 
8.5 ml + 1.5 
ml di ACD-A 
16 1 191 g for 6’  1072900 
(84.01): lower 
PC fraction 
652000 (56.47): 
upper PC 
fraction 
 “The methodology used in 
this study allows the 
concentration of a number 
of platelets and 
TGF-β1 that might be 
acceptable for a biological 
effect for clinical or 
experimental use as a 
regenerative therapy in 
dogs.” 
Souza et 
al, 2012 
Vet Comp 
Orthop 
Traumatol 
8 ml + 2 ml di 
sodio citrato 
21 2 160 g for 20’ 
(with white 
blood cells and 
first 2 mm of 
red blood cells) 
400 g for 15’ 
 
In all animals, 
the minimum 
increase in 
platelet count 
of 338% 
required for 
the PRP was 
obtained.  
1 ml “Platelet rich plasma can be 
used as an adjuvant therapy 
because it may promote 
better bone healing of a 
radial ostectomy treated 
with external skeletal 
fixation 
in dogs.” 
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Table 2: Articles relating to PRP obtained from rabbits using a home made methods (Articles with positive outcome are highlighted in green, Articles with negative 
outcome are highlighted in red). 
Authors Joural Subject
s (n°) 
Whole blood  
(ml)and 
anticoagulan
t 
Centrifugatio
n (n°) 
Speed 1° 
centrifugatio
n 
Speed 2° 
centrifugatio
n 
Platelet 
concentratio
n in PRP 
Amount 
of PRP 
obtained 
(ml) 
Conclusion 
Efouglu 
et al., 
2004 
J Oral 
Maxillofa
c Surg 
23 9 ml in EDTA 2 300g for 10’ 
As suggested 
by Marx, all of 
the plasma and 
the top 
erythrocyte 
layer were 
transferred to 
an empty 
tube 
5000g for 5’    
  Group 
1: 13 
   Group 1:  
lower half is 
PRP  
Mean : 
1061000/µL 
(122.2037%) 
  
  Group 
2: 10 
   Group 2: 
lower third is 
PRP. 
Mean: 
3134500/µL 
( 429.6306 %) 
It was not 
possible 
to repeat 
the cell-
counting 
procedure
s because 
of 
the limited 
volume of 
PRP and 
PPP 
available 
 
Andrade
, et al., 
Oral Surg 
Oral Med 
50 9 ml + 1.5 ml 
di ACD 
2 300 g for 10’ a 
22 °C 
5000g for 5’ 
within the 
Mean 2324.08 
x 10³/µL, 
 “The protocol 
evaluated 
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2008 Oral 
Pathol 
Oral 
Radiol 
Endod 
rotor 
acceleration 
curve of 60’’ 
and 
rotor braking 
curve of 55’’ 
same 
parameters of 
temperature, 
acceleration, 
and braking 
curves. 
DS 925.34, 
Median 
2172.50 x 
10³/µL 
produces a 
good PRP. 
Whole-blood 
parameters can 
predict PRP 
features. Whole 
blood 
Ht is an 
important 
variable for 
PRP 
preparation and 
PRP cytometry 
characterization
. PRP platelet 
count 
is dependent 
upon whole-
blood platelet 
count. “ 
         “It was 
experimentally 
shown that 
PRP with high 
platelet counts 
can be prepared 
using this 
modified 
method without 
the need for 
costly 
autotransfusion 
systems.” 
Nagata- Eur J 10 5 ml Group I:  160 G for 6’ - 781.875 1.2 ml “double-
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Messora 
et al., 
2010 
Dent 1 centrifugation At room 
temperature 
(±217.693)/µ
L 
centrifugation 
protocol 
resulted in 
higher platelet 
concentrations 
than did the 
single-
centrifugation 
protocol. 
However, 
the double-
centrifugation 
protocol caused 
alterations in 
platelet 
morphology 
and was more 
sensitive 
to small 
processing 
errors.” 
   5 ml Group II: 2 
centrifugations 
160 G for 20’ 
At room 
temperature 
400 G for 15’ 
At room 
temperature 
1986875 
(± 685.020) 
/µl 
0.5 ml  
Obata et 
al., 2012 
Arthritis 
Research 
& 
Therapy 
12 10 ml + 1 ml 
citrate 
dextrose-A 
solution 
2 330 g for 15’ 1000g for 10’  mean 
57525000 ± 
3937000 /μL, 
about 29 times 
greater than 
that of whole 
blood  
 
 “We have 
shown that the 
administration 
of autologous 
PRP-releasate 
was effective in 
restoring disc 
height and 
increasing 
chondrocytic 
80 
 
cells in the IVD 
of the rabbit 
anular puncture 
disc 
degeneration 
model” 
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Table 3: Articles relating to equine PRP that use home made methods for PRP production (Articles with positive outcome are highlighted in green, Articles with 
negative outcome are highlighted in red) 
Authors Joural Subjects 
(n°) 
Whole blood  
(ml)and 
anticoagulant 
Centrifugation 
(n°) 
Speed 1° 
centrifugation 
Speed 2° 
centrifugation 
Platelet 
concentration 
in PRP 
Amount of 
PRP 
obtained 
(ml) 
Conclusion 
Arguelle, 
Carmona 
et al., 
2006 
Research in 
Veterinary 
Science 
26 125 ml divided 
in 25 tubes 
with sodium 
citrate 3.8% 
I group: 1 
centrifugation (5 
ml in 8 tubes) 
120 g for 5’  PC a platelet 
concentration 
45%, 
229000/µL 
(126000-
364000) 
PC b platelet 
concentration 
44% 
(228000/µL, 
125000-
361000) 
PC a (50% 
fraction 
closet to the 
BC) 
PC b (50% 
fraction of 
the 
supernatant 
above PC a)  
 
“The platelet 
collection 
efficiency and 
TGF-β1 
concentration 
efficiency were 
higher for PCs 
obtained by the 
single 
centrifugation 
tube method 
compared with 
PCs obtained by 
the double 
centrifugation 
tube method. “ 
    II group: 2 
centrifugation  
120 g for 5’ 
 (g and time 
used 
determined 
after 
preliminary 
studies (data 
not shown) 
done in the 
same laboratory 
240 g for 5’ PC c platelet 
concentration 
71%, 272000 
(138000-
479000)  
PC d platelet 
concentration 
21%, 191000 
(112000-
295000) 
PC c (lowe 
25% fraction 
of the 
centrifugated 
PC a sample) 
PC d 
(remaining 
upper 75% 
fraction) 
“The results of 
this study let us 
think that PC b 
and PC c are 
maybe 
preferable for 
the clinical use 
in equine 
patients with 
musculoskeletal 
pathologies. “ 
Arguelles 
et al., 
2008 
Vet Rec 5 5ml * 8 tubes 1 120 G for 5’ 
 
 229.000 /µL  “All the horses 
had returned to 
their pre-injury 
level of 
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performance by 
six months after 
the completion 
of the 
treatment, and 
none of them 
had suffered a 
recurrence after 
20 months.” 
   5 ml *16 tubes 2 120 G for 5’ 240g for 5’ 272.000 /µL   
De Rossi 
et al., 
2009 
Acta 
Cirurgica 
Brasileira 
6 10 ml in 2 
tubes with 10% 
sodium citrate 
2 300g for 10’ 
 
640g for 10’ at 
room 
temperature 
 1600000/μL  “Wounds 
treated with 
PRP gel exhibit 
more rapid 
epithelial 
differentiation 
and enhanced 
organization of 
dermal collagen 
compared to 
controls in 
equine 
Torricelli 
et al., 
2011 
International 
Orthopaedics 
13 Equine whole 
venous blood 
was collected 
with sodium 
citrate. 
2 200 g for 5’ 1000g for 15’ 751×10³/μL  the platelet 
concentration 
predicted the 
healing time: 
significantly 
faster recovery 
(p= 
0.049) was 
observed in 
cases of PRP 
with more than 
750× 
103/μl 
platelets.” 
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6. Effectiveness of manual double centrifugation 
method for preparation of Canine Platelet-Rich 
Plasma  
 
6.1 Abstract 
The platelet-rich plasma (PRP) is a product derived from whole blood with a 
platelet concentration higher than normal range in a small amount of plasma. 
Regenerative capacities of PRP deriving from platelet growth factors. For this 
reason PRP is used in human and veterinary medicine for its capacity to 
stimulate cell proliferation, angiogenesis, wound healing, production of 
fibroblasts, collagen, osteoblasts and to accelerate the healing process. In 
veterinary medicine the methods use to produce PRP are not standardized and 
extremely numerous. The aim of this study was to describe and evaluate a 
manual double centrifugation method to produce canine PRP. 28 blood samples 
(5-10 ml with 1 ml of sodium citrate) from 28 healthy dogs were analyzed. The 
first centrifugation  (2500 rpm for 10’) resulted in two components, blood cell 
component in the bottom and serum component (SEC) in the upper fraction of 
the tube. All SEC, the buffy coat and the first 2 mm of red blood cell was 
submitted to a second centrifugation (4000 rpm for 15’) and  resulted  in two 
components, platelet poor plasma (PPP)  and platelet pellet in the bottom. The 
amount of PPP used to resuspend platelet pellet was calculated considering that 
all platelets previously present in the SEC was in platelet pellet. Then 50% of the 
calculated PPP was used to resuspend platelet pellet with the aim to obtain the 
final platelet concentration of about 1 million /µl.  
The method proposed in this study permitted in 14/28 samples of PRP (50%)  
to reach the human target of 1 milion platelets/µl ± 20% and/or the target of 
three to six fold platelet concentration in whole blood. According to a part of 
human literature the concentration of platelet in PRP does not seem to be 
necessarily linked to its effectiveness. For this reason to complete the evaluation 
of the proposed method will be necessary assess the platelet viability and after 
apply the PRP in vivo.  
 
6.2 Introduction 
The platelet-rich plasma (PRP) is a product derived from whole blood, 
characterized by the presence of a platelet (PLT) concentration higher than the 
normal range in a small volume of plasma (Marx et al., 2001). 
The numerous growth factors present in the platelet alpha granules (Derived 
Platelet Growth Factor, Epidermal Growth Factor, Insulin Growth Factor, 
Vascular Endothelial Growth Factor etc.) are capable of stimulating cell 
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proliferation, angiogenesis, wound healing, production of fibroblasts, collagen, 
osteoblasts and to accelerate the healing process (Anitua et al., 2004).  
In the human medicine the regenerative capacity of PRP are mainly applied in 
orthopedic surgery, maxillofacial surgery, dentistry, medicine, cosmetic surgery 
(Martinez-Zapata et al., 2009, Eppley B et al., 2006) and in dermatology such as, 
the healing of chronic skin ulcers (Driver et al., 2006). 
In veterinary medicine studies about the production and application of PRP are 
very scarce. In the most studies animals were used as models for human 
medicine (Jensen et al., 2004, , Casati et al., 2007, Li et al., 2009, Rai et al., 2007, 
Nagata et al., 2010). The use of PRP for therapeutic purpose in animals has been 
documented in musculoskeletal, tendal and soft tissue injuries in horses 
(Arguelles et al., 2008, Waselau et al., 2008, Bosch et al., 2011, Torricelli et al., 
2011) and in a single dog with a large cutaneous lesion (Kim et al., 2009). 
In veterinary medicine only few studies were conducted and  there is a lack of 
suitable standardization and definition of the different PRP preparations 
(Arguelles et al., 2006, Textor et al., 2011 , Nagata et al., 2010). In particular in 
canine species there are few studies that described and evaluated manual method  
(Souza et al., 2012, Ferraz et al., 2007, Silva et al., 2012) or  semi-authomated 
method (Stief et al., 2011) to produce canine PRP. 
In dog the potential use of autologous thrombocytic growth factor to accelerate 
tissues regeneration requires improved methods of isolating platelet-rich plasma 
(PRP) (Weibrich et al.,  2003). The manual protocols described to prepare PRP 
differ widely and do not give detailed information about the amount of starting 
whole blood, the type of anticoagulant used, the times and speed of 
centrifugation used, whether or not buffy coat was included in the final PRP and 
the final platelet concentration obtained in PRP (Rabillard et al., 2009, Silva et al., 
2012, Souza et al., 2012, Kim et al., 2009). To date there are no exhaustive 
studies carefully describing the manual method to obtain PRP in the dog and 
there is not yet been identified the most effective concentration of PLT in PRP 
in the canine species.  The arbitrary target use in human medicine of platelet 
concentration in PRP of 800000-1000000 plt/µL, that is three to six fold platelet 
concentration in whole blood has been proven as clinically effective by several 
studies. Nonetheless the relationship among platelet concentration, growth 
factor concentration and clinical effectiveness is far from being clear (Mazzucco 
et al., 2009) both in human that in veterinary medicine. Thus the aim of this 
study was to clearly describe a manual double centrifugation method to obtain 
small amount of autologous canine PRP starting to a relative small amount of 
whole blood.  
 
6.3 Material and methods 
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Twenty eight adult healthy dogs weighing from 20 to 45 Kg, both sexes, between 
1 and 7 years were use.  With owners consent the blood samples were extracted 
from each dog fasted from 12 hours  during routine heartworm test screening 
control for blood donor dogs.    
Five to ten milliliter of blood were collected from the cephalic vein using large 
gauge needle (21 gauge) in order to minimize either animal trauma and  platelet 
activation.  
The blood collected was immediately placed into test tube with a conical bottom 
contains 1 ml of sodium citrate 3.8% (Tube A) (Photo 1a) and gently sloped 
several time to mix the blood with the anticoagulant. All samples were 
maintained at room temperature (18-25 ° C), processed and analyzed within 24 
hours of sampling.  
On all whole blood (WB) samples complete blood count was performed using 
an automatic analyzer (CELL-DYN 3500 Plus, Abbott, Germany). All samples 
were accurately maintaining on laboratory blood rocker  for minimum 5 minutes 
before the platelet count.  
 
6.3.1 Protocol of PRP preparation 
All samples were subject to the same double centrifugation protocol; the first in 
order to divide blood cells elements to plasma, the second one to concentrate 
platelets into a single pellet.    
First centrifugation: The blood samples were centrifuged at 610 g (2500 rpm) for 
10 minutes at room temperature using a laboratory centrifuge (EBA 20 – 
Hettich, Germany) resulting in two  components, blood cell component (BCC) 
in the bottom of the tube and serum component (SEC) in the upper fraction of 
the tube. In all cases was possible to see buffy coat between the two components 
(Photo 1b). 
To be sure to include the buffy coat (rich of young giant platelets) on the SEC 
fraction, a mark was made 2 mm below the line between  BCC and SEC. Then 
all contents above this mark was pipetted and transferred to another 10 ml 
graduated conical tube without anticoagulant (Tube B). In particular firstly 80% 
of the top SEC was pipetted and transferred in tube B with a 1000µL pipette 
(adjustable manual air cushion pipette 100-1000 µL, Eppendorf, North America) 
while remaining SEC (included the buffy coat) was pipetted with a 200 µL 
pipette (adjustable manual air cushion pipette 10-200 µL, Eppendorf, North 
America) to be more precise.  
Before the second centrifugation, the quantity of SEC was recorded and the  
count of PLT on the SEC was performed using an automatic analyzer (CELL-
DYN 3500 Plus, Abbott, Germany). 
Second centrifugation: Tube B was then centrifuged again at 1600 g (4000 rpm) 
for 15 minutes resulting in two components: platelet poor plasma (PPP) in the 
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upper fraction of the tube and platelet pellet in the lower fraction (visible as a red 
button on the bottom of the tube) (Photo 1c).  
The PPP of each tube was pipetted and transferred to another 10 ml test tube 
without anticoagulant. 
The amount of ml of PPP used to resuspend the platelet pellet was calculated 
considering that all platelets previously present in the SEC were collected inside 
the platelet pellet. Then the amount of PPP used to suspend the platelet pellet 
was calculated with the aim to obtain the final concentration of PLT of about 1 
million platelets /uL (PRP)  (Marx et al., 1998, Marx et al., 2001).  
We decided to resuspend the pellet in 50% of the amount of  PPP indicated by 
the calculation to compensate the platelets lost due to a possible non-total 
precipitation of platelets in the pellet and to the operator. 
The solution thus obtained (PRP) was pipetted sometimes gently in order to 
disrupt and resuspend any platelet aggregates.  
The platelet and leukocyte count and the haemoglobin concentration were 
automatically determinated  using CELL-DYN 3500 Plus ( Abbott, Wiesbaden, 
Germany) in whole blood, SEC and PRP. 
All samples were accurately maintaining on laboratory blood rocker  for 
minimum 5 minutes before the platelet count.  
To establish the linearity of Cell-Dyn 3500 to count canine platelet over the 
canine PLT normal value a pooled PRP sample with high platelet concentration 
(1 ml volume; 863000 plt/µL) obtained from the same unit of canine fresh 
whole from Department Veterinary Blood Bank, was assessed  at different 
dilutions. 
To establish the inter-assay variation of the procedure 10 blood samples of 8 ml 
from one unit of canine fresh whole blood obtained from Department 
Veterinary Blood Bank were subject to the protocol of PRP preparation on the 
same day. The coefficient of variation (CV) was calculated as (SD/mean)x100.  
 
6.4 Statistical analysis and Platelet counting 
All quantitative measurements were described using summary statistics (mean, 
standard deviation, median, minimum, maximum).Mean, standard deviation and 
median of  whole blood (ml) used to produce PRP, platelet concentration in WB, 
SEC and PRP, ml of SEC obtained after the first centrifugation, PPP aliquot 
used for the resuspension of platelet pellet were calculated after calculating 
normal distribution of parametric data using the D’Agostino-Pearson test.  
Mean, standard deviation, median of hematocrit (Ht), leukocyte (WBC) and 
platelet count (PLT) from WB and PRP were calculated after calculating normal 
distribution of parametric data using the D’Agostino-Pearson test.  The 
difference between Ht, WBC and PLT between WB and PRP were tested by 
carried out based on Mann-Whitney test for independent samples. 
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The influence of these variables on PRP value and the correlation among each 
parameter in whole blood and PRP were calculated using Spearman’s coefficient 
of rank correlation (rho).  Also the correlation between ml of WB use to produce 
PRP, platelet concentration in SEC and platelet concentration in PRP were 
calculated using Spearman’s coefficient of rank correlation (rho). 
To assess the platelet increase over whole blood baseline value was used the 
following equation:  
Platelet concentration over whole blood baseline = ( Platelet Count in PRP/ 
Platelet count in whole blood) x 100 (Marx et al., 2004). 
To establish the inter-assay variation of the procedure 10 blood samples of 8 ml 
from one unit of canine fresh whole blood were subject to the protocol of PRP 
preparation on the same day. The coefficient of variation (CV) was calculated as 
(SD/mean)x100. 
For all test significance was set at P < .05. Statistical analyses were performed 
using commercial software (MedCalc Software, Mariakerke, Belgium). 
 
6.5 Results 
PRP was prepared in approximately 30 minutes. Twenty-eight samples were 
subjected to double centrifugation methods. The time and speed of 
centrifugation was chose based on the previous centrifugation  that failed to 
achieve any significant  platelet enrichment. After various assays optimal platelet 
enrichment was achieved with double centrifugations at the speed of 2500rpm 
for 10 minutes and 4000 rpm for 15 minutes respectively.  
Number of platelets, mean, standard deviation and median of platelet 
concentration in WB, SEC and PRP, ml of SEC obtained after the first 
centrifugation, PPP aliquot used for resuspension of platelet pellet, and amount 
of platelet concentration over whole blood baseline (%) are reported in Table 1.  
Platelet count of 1 million/uL ± 20% was achieved by 12/28 samples (42.9%) 
while platelet concentration (%) of minimum 300% was achieved by 11/28 
samples (39,3%). Taken together 14/28 (50%) samples has reached the target 
(platelet concentration higher than 800000 plt/uL or a minimum of three fold 
platelet concentration in whole blood) (Table 1) (Photo 1).  
Mean, standard deviation, median of hematocrit (Ht), leukocyte (WBC) and 
platelet count (PLT) in WB and PRP and statistical analyses of difference were 
reported in Table 2.  
Significant and positive correlations between platelet count in WB and in PRP 
(rho = 0.490, p= 0.0081) and between WBC in WB and in PRP (rho = 0.384, p 
= 0.0435)  were observed. No correlation between Ht in WB and Ht in PRP 
(rho = -0.157, p = 0.4447) was presented. 
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No correlation was presented between ml of  WB use to produce PRP and 
platelet concentration in SEC (rho = 0,1665, p = 0,5167) and between ml of WB 
and platelet concentration in PRP (rho = 0,04838, p = 0,8069).  
The CV of platelet count performed on 10 samples of PRP obtained from one 
fresh whole blood unit  was 8.43 (Table 3)  
The linear correlation value between the full strength and the diluted platelet 
counts on pooled PRP sample was found to be r = 0.98. Mean of recovery was 
16,4% (Table 4). 
 
Figure 1: a - Tube A containing whole blood, b -Tube A after first centrifugation with visible buffy 
coat, c - Tube B after second centrifugation with visible platelet pellet on the bottom of the tube 
 
a b  
c  
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Table 1: Data obtain from 28 samples submitted to manual double centrifugation for produce canine 
PRP 
Sampl
es 
Ml of 
whole 
blood 
PLT  in WB 
(/uL) 
PLT in  SEC 
(/uL) 
ml 
SEC 
ml PPP 
for 
resuspension 
PLT in 
PRP 
PLT concentration 
(%) 
1 7 204000 250000 3,5 0,4 818000 401 
2 9 313000 160000 4,4 0,4 1388000 443 
3 8 252000 151000 3,2 0,2 427000 169 
4 6 194000 48800 3 0,1 658000 339 
5 5 193000 60700 3,2 0,1 1348000 698 
6 5 98900 57400 2,5 0,1 170000 172 
7 5 98100 93000 4,1 0,2 569000 580 
8 7,2 442000 612000 3 0,9 825000 187 
9 7,5 629000 942000 3,5 1,7 997000 159 
10 7 395000 344000 2,3 0,4 997000 242 
11 6,5 321000 320000 2,5 0,4 740000 231 
12 7 355000 277000 3 0,4 559000 157 
13 7 340000 277000 3 0,4 500000 147 
14 8,5 237000 268000 3 0,4 620000 262 
15 8,5 357000 425000 4 0,9 1135000 318 
16 9 314000 375000 3,5 0,7 785000 250 
17 9 156000 234000 4 0,5 457000 293 
18 10 140000 151000 4 0,3 260000 186 
19 9,5 106000 147000 4 0,3 211000 199 
20 9 163000 134000 4 0,3 172000 106 
21 9 375000 504000 4,4 1,1 1411000 376 
22 9 241000 104000 3,5 0,2 1121000 465 
23 8,5 270000 317000 2,5 0,4 540000 200 
24 8,5 275000 360000 2,5 0,5 752000 273 
25 10 167000 167000 4 0,3 873000 523 
26 9 174000 223000 3 0,3 1490000 856 
27 9 346000 390000 3,8 0,7 1390000 402 
28 10 247000 387000 2 0,4 559000 226 
        
Mean 8,03  
264392,9 
 
277817,9 
 
3,3357
14 
 
0,464286 
 777571.43 
316,4286 
 
SD 
1,5238
09 
 
118922,7 
 
191340,2 
 
0,6717
66 
 
0,344496 
 394454.37 
178,8048 
 
 
Media
n 8,5 
264392,9 
 
259000 
 3,35 0,4 746000 
256 
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Figure 1: Platelet count in WB and PRP of each sample. 
 
 
 
 
Table 2: Mean, standard deviation and median values of Hematocrit (Ht), leukocytes (WBC) and PLT 
on WB and PRP and Spearman’s coefficient of rank correlation (rho) results on 28 samples subjected 
to home made double centrifugation 
 
Variable Sample Mean SD Median Distribution P Mann-
Whitney 
Spearman’s 
coefficient 
(rho) 
Ht (%) Whole 
blood 
40.9 4.939 40.25 Normal (p = 
0.9166) 
< 0.0001 rho = -0.157,  
p = 0.4447) 
 PRP 4.6988 3.6668 3.8250 Not normal (p 
< 0.0001) 
  
WBC(/µL) Whole 
blood 
9537,9 2.9540 9035 Normal (p = 
0.2838) 
< 0.0001 rho = 0.384,  
p = 0.0435   
 PRP 28588,2 24.6352 19950 Not normal (p 
= 0.0004) 
  
Platelet 
count (PLT/ 
µL) 
Whole 
blood 
264392.86 118922.71 249500 Not normal (p 
= 0.0226) 
< 0.0001 rho = 0.490  
p= 0.0081 
 PRP 777571.43 394454.37 746000 Normal (p = 
0.4327) 
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Table 3: Data about  repeatability of manual double centrifugation method to obtain canine PRP on 10 
samples obtained from one unit of fresh whole blood   
Samples  PLT in Whole Blood PLT in PRP (/µL) % 
1 455000 956000 210,11 
2 431000 815000 189,1 
3 408000 1033000 253,19 
4 417000 903000 216,55 
5 406000 1029000 253,45 
6 387000 910000 235,14 
7 395000 901000 228,1 
8 389000 1008000 259,12 
9 376000 1062000 282,45 
10 377000 1044000 276,92 
Mean 404100 
 
966100 
 
240,413 
 
SD 25004,22 
 
81481,35 
 
29,96885 
 
 
 
Table 4: Platelet concentration and percent recovery of platelet using Cell-Dynn 3500 Analyzer on a 
diluted PRP pooled sample.  
Dilution  Expected (x 1000/µL) Observed (x 1000/µL) Recovery  
1:1 858 858 100 
1: 0.75 643.5 753 117 
1: 0.5 429 500 116.5 
1: 0.25 214.5 248 115.6 
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Photo 1: PRP smear stained with a rapid method for cytological preparations (MGG STAIN QUICK 
BIO-OPTICA) (magnification x1000). This sample has reached both targets (PLT count 1388000/µL, 
platelet concentration 443%). All components are easily recognizable). 
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6.6 Discussion 
The aim of this study was evaluated a manual double centrifugation protocol to 
obtain canine PRP. Our method not requiring special equipment and permit to 
obtain the final product in 30 minutes. In our study  the arbitrary target of 1000 
x 10³platelet/µL ± 20% used in the majority of human medicine studies has 
been reached in 12/28 samples (42.9%) while the target of three to six folds 
platelet concentration in whole blood was achieved by 11/28 samples (39,3%). A 
total of 14/28 samples (50%) reached one or both the human target for PRP. 
A mean of 0,5 ml of PRP starting from a mean 8 ml of whole blood was achived 
in our study similar to the result of Jensen et al. (2004) that isolated 0,6 ml of 
PRP from each test tube containing 9 ml of whole blood. 
The mean of platelet concentration in our PRP is 777571.43 /µL. This value is 
lower respect other studies for producing canine PRP with home made method 
(Kim et al., 2002, Choi et al., 2004, You et al., 2007, Ning et al., 2009, Zhu et al., 
2012) but higher respect other studies (Casati et al., 2006, Ferraz et al., 2007).  
The speed of the centrifugation may influenced the final PRP concentration 
(Casati et al., 2006, Ferraz et al., 2007,  Silva et al. 2012). We have varied the 
force and time of centrifugation in order to obtain the optimal platelet 
enrichment on the basis of the previous studies conducted on the dogs (Choi et 
al., 2004, You et al., 2007, Li et al., 2009, Kim et al., 2009). In particular our 
speed and time of centrifugation are similar to other three studies (You et al, 
2007, Choi et al, 2004, Kim et al, 2009) but in these studies the target of 1million 
of platelets/µL was reached. Also the anticoagulant may have influence on the 
PRP platelet concentration,  Landsberg et al. (2000) reports that EDTA gave 
higher yields than the citrate but seems that the platelets appeared to be more 
damaged.  Although EDTA gave greater yields of platelets they appeared damage 
by the presence of the EDTA while the citrated-derived plasma had sufficient 
platelets to produce good clots (Landsberg et al., 2000) 
Even if the target has been reached in 50% of the samples the significant 
difference between PLT in WB (median  249500/µL) and PLT in PRP (median 
746000/µL) (P < 0.0001) and the significant and positive correlations between 
platelet count in WB and platelet count in PRP (rho = 0.490, p= 0.0081) are 
indices of the  capacity of the method to  concentrate the platelets in a small 
amount of plasma. Furthermore  the significant difference between WBC in WB 
(median  9035/µL) and WBC in PRP (median 19950/µL), (p < 0.0001) and the 
significant correlation between WBC in WB and WBC in PRP (rho = 0.384, p = 
0.0435) with WBC in PRP higher that WBC in WB are indices of good buffy 
coat inclusion during the preparation method. In buffy coat are in fact present 
giant and young platelets.  
The variables to be assessed during the PRP production are numerous and all 
can influence the final result. Also for this reason, the literature is extremely 
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varied with regard to method of production, the final platelet concentration and 
clinical efficacy of PRP. Platelets are extremely delicate blood components that 
may undergo changes in number or quality at each step of the production of 
PRP. Platelets are easily stressed by withdrawal of blood, by subsequent 
manipulations (amount, rate, duration of centrifugation, the centrifuge and 
quality settings for acceleration and breaking), the operator's manual, the 
anticoagulant  used. Furthermore platelets are labile particles that quickly lose 
their properties during storage. All these variables can lead to changes in both 
the quantity of platelets found in the final product that their quality as a possible 
activation of the product during any of the stages of production leads to the 
release of growth factors, most of which will be lost with the removal the 
plasma. 
Although the biological rationale for the use of PRP is theoretically sound, both 
in human that veterinary medicine, the precise methodology that will result in the 
optimal benefits from this therapy is yet to be elucidated. In particular the 
precise PRP concentrations that would be ideal are yet to be determined. The 
majority of human studies take the definition of PRP from 2 studies from Marx 
(Marx et al, 1999, Marx et al, 2001) which report that a good PRP could have 1 
mln platelets /µL in 5-ml volume of plasma or a minimum 338% increased in 
platelet compared to whole blood. At the same way also in veterinary medicine it 
is used the same target of “good PRP” even if there are differences between 
human platelets and platelets of veterinary species regarding  platelet size, 
optimal centrifugation for their isolation and platelet reactivity. In studies 
conducted on animals the different home made protocols proposed have 
obtained platelet concentration in PRP between 400 and 2000 x 10³ plt/µL in 
dog, between 1000 and 5700 x 10³ plt/µL in rabbit and between 200 and 1600 x 
10³ plt/µL  in horse with different in vivo effects. A canine platelet 
concentration of 460.000 plt/µL (320% of whole blood) seem to be not 
sufficient to promote bone formation (Casati et al., 2007) while a platelet 
concentration of 1 milion/µL or more seem to be effective in some studies 
(Ning et al., 2009, You et al., 2007) and not effective in others (Rabillard et al., 
2009, Zhu et al., 2012) to promote osteogenesis and vascularization. In rabbit 
(Weibrich et al., 2004) advantageous biological effects for bone regeneration 
seem to occur when platelet concentration in PRP was approximately 1 mln /µL 
with lower effects at suboptimal concentration and paradoxically inhibitory 
effect at higher concentration. The similar inhibitory effect is reported in a study 
on canine PRP (Choi et al., 2004).  
A recent study (Torricelli et al., 2011) carried on the horse has already shown 
that platelet concentrations greater than 750000/µL significantly accelerate the 
healing time of wounds.  
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So it would seem that the activity of the PRP is more related to the 
concentration of growth factors and their activation rather than to the 
concentration of platelets. Growth factors present in PRP are likely to depend 
on the particular technique used to obtain the PRP ( Weibrich et al., 2003) 
It must be noted that numerous controversial results exist for the platelet 
concentration request to have therapeutic effects associated with PRP alone and 
in combination with bone substitutes, in animal studies and in particular in the 
dogs (Rai et al., 2007, Marx et al.,  200,). For example in a study conducted by  
Jansen et al. (2004) a canine PRP with 1 mln platelet/µL did not show significant 
effect in bone formation  while in a study conducted by Rai et al. (2007) a canine 
PRP of 450000 platelet/µL  demonstrated activity  in the treatment of critical-
sized defects of the mandible.  
In light of the currently reported in bibliography our method allows to obtain a 
"good PRP" in 50% of cases. The amount of PRP (mean 0.5 ml) we obtained 
starting from a minimum quantity of blood (5-9 ml) allow the application in the 
field of dermatology and ophthalmology. This method could be used in clinic, if 
only limited volumes of PRP are needed. 
In addition the inter-assay variation of our method evaluated on 10 samples 
taken from the same fresh whole blood units gave a value of 8.43. To our 
knowledge there are no studies that have evaluated the inter-assay variation of 
method for the production of PRP. For this reason, we can only compare our 
data with the value of inter-assay reported for platelet counts in human medicine 
(Westgard, 2012). In human medicine, a within-subject biologic variation for 
platelet count of 9.1 is considered acceptable. Therefore on this basis we can 
assume that our method performed by an experienced operator gives an 
acceptable value of inter-assay. 
However, we believe that it is necessary to improve the protocol proposed by us. 
The points to be evaluated will be the use of a different anticoagulant (such as 
ACD), the production of PRP within 6 hours of collection of whole blood, the 
use of a centrifuge which allows to set acceleration and deceleration and the 
assessment of new speed and centrifugation time in order to allow a better 
division of the various blood components and to minimize the resuspension of 
platelets in the plasma portion during braking. Additionally we would like to 
confirm the automatic platelet counts by performing counts with 2 different 
machines (for example Cell Dyn and ADVIA 120) to minimize the possibility of 
an erroneous platelet count. 
Unfortunately, in our study, we evaluated only the quantity of platelet in PRP 
samples and not the platelet integrity (BIAS). In particular qualitative alterations 
in the platelets may affect the regenerative potential of PRP for the loss of 
bioactive growth factors. 
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To complete the evaluation of this method to produce canine PRP will be 
necessary 
 assess the platelet viability (for example using tests like pH, hypotonic stress, P-
Selectin and platelet aggregation levels) and  PRP application in vivo. 
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Ministero dellaSalute 
DIPARTIMENTO PER LA SANITÀ PUBBLICA VETERINARIA, LA NUTRIZIONE 
E LA SICUREZZA DEGLI ALIMENTI 
DIREZIONE GENERALE DELLA SANITÀ ANIMALE E DEL FARMACO 
VETERINARIO 
UFFICIO IV 
 
Linea guida relativa all’esercizio delle attività sanitarie riguardanti la medicina 
trasfusionale in campo veterinario. 
 
 
 
Campo di 
applicazione 
La presente linea guida si applica al sangue intero di origine animale prelevato da 
animali di proprietà di persone giuridiche e/o fisiche  per lo scopo trasfusionale. Essa non 
si applica ai prodotti derivati dal sangue, regolati dal decreto legislativo del 6 aprile 2006, 
n.193. 
 
 
 
Prelievo di 
sangue intero 
 
 
Si  definisce  “sangue  intero”  il  sangue  prelevato,  per  lo  scopo  trasfusionale,  dal  
donatore riconosciuto idoneo, utilizzando materiale  sterile e sacche regolarmente 
autorizzate dal Ministero della salute,contenenti una soluzione anticoagulante-
conservante. 
Il prelievo di sangue intero deve essere effettuato da un medico veterinario, attuando una 
metodica che garantisca asepsi, con un sistema a circuito chiuso, compatibilmente con 
la specie animale, e con  dispositivi  non riutilizzabili.  Il  direttore  sanitario della  
struttura  trasfusionale  definisce  un protocollo  dettagliato  delle  procedure  di  prelievo,  
con  particolare  riguardo  alla  detersione  e disinfezione della cute prima della 
venipuntura, e vigila sulla sua applicazione. Nel caso in cui si rendesse necessaria più di 
una venipuntura deve essere utilizzato un nuovo dispositivo di prelievo. Preliminarmente 
al prelievo è necessario ispezionare le sacche per verificare l’assenza di eventuali difetti, 
la scadenza, la corretta quantità di anticoagulante in esse contenuta ed il suo aspetto. 
Dopo ciascun prelievo, i contenitori e le sacche debbono essere accuratamente 
ispezionati per verificare l’assenza di qualsiasi difetto. Debbono essere inoltre adottate 
misure volte ad evitare ogni possibilità di errore nell’etichettatura della sacca e delle 
corrispondenti provette. 
Nell’allegato 2 alla presente linea guida sono illustrate le fasi della procedura da 
seguire per la raccolta del sangue. 
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Idoneità alla donazione e 
benessere animale 
 
 
Occorre anzitutto valutare le condizioni generali di salute dell’animale donatore, con 
particolare attenzione agli stati di debilitazione, iponutrizione, edemi, anemia, ittero, 
cianosi, dispnea e lesioni cutanee. 
Ad ogni donazione l’animale donatore deve essere sottoposto obbligatoriamente agli 
esami di laboratorio di cui all’allegato 1 alla presente linea guida, volti ad escluderne gli 
stati patologici e la positività  degli  indicatori  delle   malattie  trasmissibili,  nonché  ad  
individuarne  le  principali caratteristiche immunoematologiche. 
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Le modalità  previste per l’attuazione della procedura di donazione di unità di sangue intero non 
devono provocare sofferenza, angoscia o danni durevoli in capo ai donatori. 
 
 
 
Preparazione, conservazione ed  etichettatura del sangue intero 
 
Il sangue intero, prelevato utilizzando materiale sterile e sacche autorizzate dal Ministero della 
salute, deve essere conservato in frigoemoteca ad una temperatura di 4°C (+/-) 2°C, per un periodo 
di tempo adeguato al tipo di  anticoagulante-conservante impiegato, che deve essere in ogni caso 
definito sulla base della sopravvivenza post-trasfusionale delle emazie uguale o superiore al 75% a 
24 ore. 
I frigoriferi utilizzati per la conservazione del sangue devono assicurare un’adeguata ed uniforme 
temperatura  al suo interno, devono essere provvisti di termoregistratore e di gruppo di continuità 
dedicato esclusivamente a questo scopo. 
 
La data di scadenza del sangue si identifica con l’ultimo giorno in cui il predetto può essere 
considerato utile agli effetti della trasfusione; la data di scadenza deve essere indicata in etichetta ed è 
consentito l’utilizzo massimo entro 30 giorni dal momento del prelievo. 
 
Sui contenitori di unità di sangue devono essere apposte etichette conformi a quanto indicato 
nell’allegato 6 alla presente linea guida. 
 
 
 
Trasporto, distribuzione e somministrazione del sangue . 
 
 
Il sangue intero deve essere trasportato in contenitori termoisolanti dotati di appositi sistemi di 
controllo della temperatura interna, ed i contenitori per il trasporto di unità di sangue devono essere 
pre-raffredati  a + 4°C. Il sangue deve essere trasportato ad una temperatura compresa tra +1° C e 
+10°C (sangue intero fresco  o conservato) . 
 
Prima della somministrazione di sangue intero ai riceventi devono essere eseguite delle indagini 
volte ad accertare la compatibilità fra il donatore ed il ricevente. 
 
Presso  ogni  struttura  dedita  alla  medicina  trasfusionale  veterinaria  deve  essere  adottato,  per 
ciascuna unità di sangue, un sistema di sicuro riconoscimento dell’animale ricevente cui la stessa 
unità è stata assegnata. 
 
 
 
Tracciabilità e registrazione dati 
 
Presso  ogni  struttura  trasfusionale  deve  essere  predisposto  un  sistema  di  registrazione  e  di 
archiviazione dei dati che consenta di ricostruire il percorso di ogni unità di sangue, dal momento 
del prelievo fino alla sua destinazione finale. 
I dati inerenti il donatore devono essere registrati e aggiornati in uno schedario donatori (cartaceo o 
informatico)  a   cura   del  direttore  sanitario  di  ogni  struttura  trasfusionale.  Le  operazioni  di 
registrazione vanno effettuate dopo che sia stata ultimata ogni singola fase di lavoro. Il registro deve 
essere conservato per tre anni presso ogni struttura  trasfusionale, e per le strutture destinate alla 
commercializzazione del sangue intero deve essere vidimato dall’ASL competente per territorio. Il 
suddetto schedario deve essere tenuto in modo da: 
 
a) contenere i dati del proprietario dell’animale; 
b) contenere i dati clinici dell’animale donatore; 
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c)  attuare la normativa vigente in materia di identificazione animale, facilitando la 
tracciabilità della donazione; 
d) consentire l’introduzione di informazioni riguardanti eventuali reazioni avverse. 
Nel  caso  di  reazioni  avverse  del  ricevente,  correlate  alla  trasfusione,  deve  essere  possibile, 
attraverso il  precitato schedario, risalire al donatore e verificare i risultati di tutte le indagini 
compiute. 
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Allegato n. 1 
 
 
ESAMI OBBLIGATORI AD OGNI DONAZIONE DI SANGUE: CANE, GATTO E CAVALLO 
 
 
A seconda della tipologia d’impiego del sangue si possono distinguere due possibili opzioni nel pannello di 
esami di laboratorio da eseguire sul donatore: 
 
•  sangue intero di pronto impiego o d’emergenza preparato all’interno della struttura veterinaria 
e da utilizzare all’interno della medesima senza possibilità di cessione ad altre strutture; 
• sangue intero reperibile in commercio. 
Lo stato di salute del donatore deve essere verificato ad ogni donazione, oltre che con una visita clinica  
accurata, anche con un pannello di esami standard che, all’occorrenza ed in particolari situazioni 
epidemiologiche,  può essere ampliato. Queste informazioni devono essere trascritte sulla cartella clinica 
dell’animale donatore, che deve essere conservata per tutta la durata dell’impiego dello stesso come donatore e 
per un anno dopo la sua esclusione o conclusione dell’attività come soggetto donatore. 
 
Nel caso di sangue intero di pronto impiego o d’emergenza, le analisi di laboratorio da eseguire sono quelle 
elencate nella tabella 1 per il cane, nella tabella 2 per il gatto e nella tabella 3 per il cavallo. Nel caso di 
sangue intero  reperibile in commercio le analisi di laboratorio da eseguire sono quelle riportate nella 
tabella 4 per il cane, nella tabella 5 per il gatto e nella tabella 6 per il cavallo. 
 
 
Tabella 1 – Cane: Elenco degli esami di laboratorio da eseguire sul sangue intero di pronto impiego o 
d’emergenza preparati all’interno della struttura veterinaria, da utilizzare all’interno della medesima e non 
cedibile ad altre strutture. 
 
 
Esame 
 
Analiti 
Gruppo sanguigno DEA 1.1° 
 
Emocromo 
n° RBC, Hgb, Hct, MCV, MCH, MCHC, RDW (morfologia RBC) 
n°  WBC,  Formula  leucocitaria  (neutrofili,  eosinofili,  basofili,  linfociti, 
monociti) morfologia WBC 
n° PLT, MPV (morfologia PLT) 
Proteine plasmatiche totali 
ricerca microscopica per Babesia spp. nel buffy coat* 
Sierologico Leishmania  Infantuma,  Ehrlichia  Canisa,  Babesia  Canisb*,  Dirofilaria 
Immitisa** 
Legenda: * alternativo all’indagine IFI per Babesia canis; ** se in trattamento profilattico regolare si può omettere 
l’esame; a= è possibile l’impiego di test rapidi di tipo ambulatoriale; b- IFI=Immunofluorescenza Indiretta. 
Codifica sigle: n°RBC=numero eritrociti; Hgb=emoglobina; Hct=ematocrito; MCV=volume corpuscolare medio; 
MCH=emoglobina corpuscolare media; MCHC=concentrazione emoglobinica corpuscolare media; RDW=ampiezza di 
distribuzione eritrocitaria; n°WBC=numero leucociti; n°PLT=numero piastrine; MPV=volume piastrinico medio; 
 
Tabella 2 – Gatto: Elenco degli esami di laboratorio da eseguire  sul sangue intero di pronto impiego o 
d’emergenza preparati all’interno della struttura veterinaria, da utilizzare all’interno della medesima e non 
cedibile ad altre strutture. 
 
 
Esame 
 
Analiti 
Gruppo sanguigno A e Ba 
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Emocromo 
n° RBC, Hgb, Hct, MCV, MCH, MCHC, RDW (morfologia RBC) 
n°  WBC,  Formula  leucocitaria  (neutrofili,  eosinofili,  basofili,  linfociti, 
monociti) morfologia WBC 
n° PLT, MPV (morfologia PLT) 
Proteine plasmatiche totali 
Ricerca microscopica per Mycoplasma haemofelis nello striscio di sangue 
Sierologico FIVa, FeLVa 
Legenda: a= è possibile l’impiego di test rapidi di tipo ambulatoriale. 
Codifica sigle: n°RBC=numero eritrociti; Hgb=emoglobina; Hct=ematocrito; MCV=volume corpuscolare medio; 
MCH=emoglobina corpuscolare media; MCHC=concentrazione emoglobinica corpuscolare media; RDW=ampiezza di 
distribuzione eritrocitaria; n°WBC=numero leucociti; n°PLT=numero piastrine; MPV=volume piastrinico medio; 
FIV=virus immunodeficienza felina; FeLV=virus leucemia felina. 
 
 
Tabella 3 – Cavallo - Elenco degli esami di laboratorio da eseguire sul sangue intero di pronto impiego o 
d’emergenza preparati all’interno della struttura veterinaria, da utilizzare all’interno della medesima e non 
cedibile ad altre strutture 
 
 
Esame 
 
Analiti 
Gruppo sanguigno Fattore Aa e Qa 
 
Emocromo 
n° RBC, Hgb, Hct, MCV, MCH, MCHC, RDW (morfologia RBC) 
n°  WBC,  Formula  leucocitaria  (neutrofili,  eosinofili,  basofili,  linfociti, 
monociti) morfologia WBC 
n° PLT, MPV (morfologia PLT) 
Proteine plasmatiche totali 
ricerca microscopica per Babesia caballi Theileria equi. nel buffy coat 
Urine Chimico, fisico e sedimento 
Parassitologico Feci 
 
Codifica sigle: n°RBC=numero eritrociti; Hgb=emoglobina; Hct=ematocrito; MCV=volume corpuscolare medio; 
MCH=emoglobina corpuscolare media; MCHC=concentrazione emoglobinica corpuscolare media; RDW=ampiezza di 
distribuzione eritrocitaria; n°WBC=numero leucociti; n°PLT=numero piastrine; MPV=volume piastrinico medio. Note: Si 
suggerisce di utilizzare solo come donatori in emergenza coloro che hanno effettuato di recente (15 gg) gli esami 
sierologici indicati nella successiva tabella 6 
 
Tabella 4 – Cane: Elenco degli esami di laboratorio da eseguire sul sangue intero reperibile in commercio. 
 
 
Esame 
 
Analiti 
Gruppo sanguigno DEA 1.1a [DEA 1.2 (Aa), DEA 7 (Tr)] 
 
Emocromo 
n° RBC, Hgb, Hct, MCV, MCH, MCHC, RDW (morfologia RBC) 
n°  WBC,  Formula  leucocitaria  (neutrofili,  eosinofili,  basofili,  linfociti, 
monociti) morfologia WBC 
n° PLT, MPV (morfologia PLT) 
ricerca microscopica per Babesia spp. nel buffy coat* 
Biochimico Proteine plasmatiche totali, Albumina, Urea, ALP, ALT 
Coagulazione PT, aPTT, Fibrinogeno 
Sierologico Leishmania  Infantuma,  Ehrlichia  Canisa,  Rickettsia  rickettsiib,  Babesia 
Canisb*, Dirofilaria Immitisa** [Borrelia Burgdorferib Brucella Canisc] 
Urine Chimico, fisico e sedimento 
Parassitologico Feci, Ricerca microfilaria nel sangue periferico 
Legenda: * alternativo all’indagine IFI per Babesia canis; ** se in trattamento profilattico regolare si può omettere 
l’esame; a= è possibile l’impiego di test rapidi di tipo ambulatoriale; b- IFI=Immunofluorescenza Indiretta; c- AGID= 
Immunodiffusione in Gel di Agar. 
 
Codifica  sigle:  n°RBC=numero  eritrociti;  Hgb=emoglobina;  Hct=ematocrito;  MCV=volume  corpuscolare  medio; 
MCH=emoglobina corpuscolare media; MCHC=concentrazione emoglobinica corpuscolare media; RDW=ampiezza di 
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distribuzione eritrocitaria; n°WBC=numero leucociti; n°PLT=numero piastrine; MPV=volume piastrinico medio; ALP= 
Fosfatasi Alcalina; ALT=Alanina Aminotransferasi; PT=Tempo di Protrombina; aPTT=Tempo di Tromboplastina 
Parziale attivato. 
 
Note: Gli esami indicati tra parentesi quadra non sono obbligatori [DEA 1.2 e 7] [Borrelia Burgdorferib Brucella 
Canisc] 
 
 
Tabella 5 – Gatto: Elenco degli esami di laboratorio da eseguire sul sangue intero reperibile in commercio 
distribuito da aziende e/o da centri di raccolta. 
 
 
Esame 
 
Analiti 
Gruppo sanguigno A e Ba 
 
Emocromo 
n° RBC, Hgb, Hct, MCV, MCH, MCHC, RDW (morfologia RBC) 
n°  WBC,  Formula  leucocitaria  (neutrofili,  eosinofili,  basofili,  linfociti, 
monociti) morfologia WBC 
n° PLT, MPV (morfologia PLT) 
Proteine plasmatiche totali 
Ricerca microscopica per Mycoplasma haemofelis nello striscio di sangue 
Biochimico Proteine plasmatiche totali, Albumina, Urea, ALP, ALT 
Coagulazione PT, aPTT, Fibrinogeno 
Sierologico FIVa, FeLVa, FIPa 
Urine Chimico, fisico e sedimento 
Parassitologico Feci 
Legenda: a= è possibile l’impiego di test rapidi di tipo ambulatoriale. 
Codifica sigle: n°RBC=numero eritrociti; Hgb=emoglobina; Hct=ematocrito; MCV=volume corpuscolare medio; 
MCH=emoglobina corpuscolare media; MCHC=concentrazione emoglobinica corpuscolare media; RDW=ampiezza di 
distribuzione eritrocitaria; n°WBC=numero leucociti; n°PLT=numero piastrine; MPV=volume piastrinico medio; ALP= 
Fosfatasi Alcalina; ALT=Alanina Aminotransferasi; PT=Tempo di Protrombina; aPTT=Tempo di Tromboplastina 
Parziale attivato; FIV=virus immunodeficienza felina; FeLV=virus leucemia felina; FIP=virus peritonite infettiva. 
 
 
 
 
Tabella 6 – Cavallo: Elenco degli esami di laboratorio da eseguire sul sangue intero reperibile in commercio. 
. 
 
 
Esame 
 
Analiti 
Gruppo sanguigno Fattore Aa, Qa, Ca, Db, Dc 
 
Emocromo 
n° RBC, Hgb, Hct, MCV, MCH, MCHC, RDW (morfologia RBC) 
n°  WBC,  Formula  leucocitaria  (neutrofili,  eosinofili,  basofili,  linfociti, 
monociti) morfologia WBC 
n° PLT, MPV (morfologia PLT) 
ricerca microscopica per Babesia caballi Theileria equi. nel buffy coat* 
Biochimico Proteine plasmatiche totali, Albumina, Urea, 
Coagulazione PT, aPTT, Fibrinogeno 
Sierologico Anemia  infettiva,  Morva,  Ehrlichia  Equi,  Anaplasma  phagocitophila, 
Babesia caballi Theileria equi.* Morbo Coitale Maligno 
Urine Chimico, fisico e sedimento 
Parassitologico Feci 
Legenda: * alternativo all’indagine IFI per Babesia spp. 
Codifica sigle: n°RBC=numero eritrociti; Hgb=emoglobina; Hct=ematocrito; MCV=volume corpuscolare medio; 
MCH=emoglobina corpuscolare media; MCHC=concentrazione emoglobinica corpuscolare media; RDW=ampiezza di 
distribuzione eritrocitaria; n°WBC=numero leucociti; n°PLT=numero piastrine; MPV=volume piastrinico medio; 
PT=Tempo di Protrombina; aPTT=Tempo di Tromboplastina Parziale attivato. 
118 
 
Allegato n.2 
 
 
IDONEITA’  ALLA  DONAZIONE  DI  SANGUE  E  PROCEDURA  DI  RACCOLTA  DEL 
SANGUE. 
 
Cane 
 
Nel cane il sangue per la donazione viene di norma prelevato dalla vena giugulare previa tricotomia 
della zona con il soggetto in stazione  quadrupedale o in decubito laterale. Devono essere impiegate 
sacche autorizzate dal Ministero della Salute e la raccolta deve avvenire per gravità. 
 
Elementi per l’idoneità alla donazione: 
 
Peso  corporeo > 25 KG 
Età 2 – 8 anni 
Regolarmente vaccinati per: Cimurro,leptospirosi, epatite, parvovirosi, rabbia 
Carattere Docile 
Quantità da prelevare 1,5-2% del volume ematico corporeo ogni 9 settimane non superando i 18 ml /Kg 
Profilassi routinarie Filariasi cardio-polmonare 
Identificazione Anagrafe di specie 
 
 
 
Gatto 
 
Nel gatto  il  sangue  per  la  donazione  viene  di  norma,  prelevato  dalla  vena  giugulare  previa 
tricotomia della zona. 
 
Vi sono 2 opzioni per la raccolta di sangue: 
 
a) l’impiego di sacche di ridotte dimensioni con appropriata quantità di anticoagulante in rapporto 
al sangue introdotto. 
b) L’uso di una siringa con aspirazione lenta. Se il sangue prelevato con la siringa deve essere 
conservato in una  sacca  per l’impiego a distanza di tempo (oltre 12 ore) all’ago cannula munita di 
tubicino va collegato un  rubinetto a tre vie prima dell’innesto sul cono della siringa. Questo 
dispositivo a tre vie consente , una volta raccolto il sangue nella siringa,  di poterlo  trasferire  nella  
sacca  di  conservazione  senza  aprire  le   vie  di  collegamento, garantendo quindi una discreta 
sterilità del prodotto emotrasfusionale. 
 
Elementi per l’idoneità alla donazione: 
 
 
Peso  corporeo 5-7 Kg 
età 2 – 8 anni 
Regolarmente vaccinati per: Calicivirosi, Herpesvirosi, Panleucopenia infettiva, Clamidiosi, Leucemia virale. 
Carattere Docile 
Quantità da prelevare 1,5-2% del volume ematico corporeo ogni 9 settimane non superando i 10 ml /Kg 
Identificazione Microchip registrato nella banca dati della struttura preposta al prelievo di sangue 
 
 
Cavallo. 
 
Nel  cavallo il sangue per la donazione viene di norma prelevato dalla vena giugulare previa 
anestesia locale  sopra il sito di prelievo e tricotomia della zona. Il sangue può essere  raccolto 
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impiegando un dispositivo che produce una pressione negativa esternamente alla sacca al fine di 
aumentare la  velocità di raccolta. 
 
Elementi per l’idoneità alla donazione: 
 
Peso  corporeo > 400 KG 
età 3 – 10 anni 
Regolarmente vaccinati per: Tetano,Influenza e Rinopolmonite 
Carattere Docile 
Quantità da prelevare 1,5-2% del volume ematico corporeo ogni 6 settimane non superando i 20 ml /Kg 
Identificazione Anagrafe di specie 
 
 
 
 
 
 
Allegato n.3 
 
 
CRITERI DI ESCLUSIONE PERMANENTE E TEMPORANEA DELL’ANIMALE 
CANDIDATO DONATORE AI FINI DELLA PROTEZIONE DELLA SUA SALUTE 
 
Al fine  della  tutela  della  sua  salute,  deve  essere  giudicato  permanentemente  non  idoneo  alla 
donazione di  sangue l’animale candidato donatore affetto o precedentemente affetto da una delle 
seguenti patologie: 
malattie  autoimmuni  e  immunomediate;  malattie  cardiovascolari;  malattie  del  sistema  nervoso 
centrale; neoplasie o malattie maligne; tendenza anomala all'emorragia; crisi convulsive. 
Nel caso in cui l’animale candidato donatore sia o sia stato affetto in modo grave o cronico da 
malattia  gastrointestinale, ematologica, respiratoria o renale, non compresa nelle categorie di cui 
sopra, il medico veterinario responsabile della selezione può avvalersi della consulenza specialistica 
prima della definizione del giudizio di  idoneità  o di non idoneità temporanea o permanente alla 
donazione. 
Possono sussistere motivi per i quali è necessario, ai fini della protezione della salute dell’animale 
candidato  donatore, rinviare la donazione; la decisione relativa alla durata del periodo di rinvio 
spetta al medico veterinario responsabile della selezione. 
La gravidanza in atto costituisce motivo di inidoneità temporanea. 
 
 
 
Allegato n.4 
 
 
CRITERI DI  ESCLUSIONE  PERMANENTE E  TEMPORANEA  DELL’ANIMALE 
CANDIDATO DONATORE AI FINI DELLA PROTEZIONE DELLA SALUTE 
DELL’ANIMALE RICEVENTE 
 
 
 
 
Inidoneita' permanente. 
 
 
Ai fini della protezione della salute dell’animale ricevente deve essere dichiarato permanentemente 
non idoneo alla donazione di sangue l’animale candidato donatore affetto o in precedenza affetto da 
una delle seguenti patologie o condizioni: 
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malattie autoimmuni e immunomediate, neoplasie maligne, diabete insulino-dipendente, epilessia, 
malattie cardiovascolari, glomerulonefrite cronica e pielonefrite, policitemia vera. 
Inoltre le seguenti specie animali sono inidonee alla donazione del sangue se hanno contratto: 
nel cane la babesiosi; nel gatto la immunodeficienza felina (FIV), la leucemia virale felina (FeLV), 
la peritonite infettiva (FIP); nel cavallo la babesiosi, l’infezione da Anaplasma phagocitophila e da 
Ehrlichia  equi,  l’infezione  che  determina  l’anemia  infettiva  (da  lentivirus  della  famiglia  dei 
retrovirus) e la morva (da Psuedomonas mallei). 
 
 
 
 
Esclusione temporanea 
 
 
In presenza di una delle sottoelencate patologie o condizioni l’animale candidato donatore deve 
essere dichiarato temporaneamente non idoneo alla donazione di sangue per un periodo di tempo di 
durata variabile in funzione della patologia o condizione rilevata: 
nel gatto la Toxoplasmosi (dopo la guarigione clinica ed in assenza di anticorpi IgM) e l’infezione 
da Mycoplasma haemofelis (dopo guarigione clinica, scomparsa del parassita dal sangue periferico e 
indagine con PCR negativa); nel  cane la Leishmaniosi (in presenza di titoli sierologici bassi e 
indagine PCR negativa sul linfonodo o sul midollo osseo), l’Ehrlichiosi (dopo la guarigione clinica 
in  presenza  di  titoli  sierologici  negativi  e  indagine  PCR  sul  sangue  periferico  negativa)  e  la 
Borreliosi (dopo la guarigione clinica in presenza di titoli sierologici negativi). 
 
 
 
Rinvio di sei mesi 
 
 
Trasfusione di  sangue  o  trattamento  con  farmaci  emoderivati,  intervento chirurgico  di  rilievo, 
Allergia ai farmaci. 
 
 
 
Rinvio di tre mesi 
 
 
Parto o interruzione di gravidanza, Somministrazione di sieri di origine animale. 
 
 
 
Rinvio di tre settimane 
 
 
Somministrazione di vaccini costituiti da virus o batteri vivi attenuati. 
 
 
 
Rinvio per 48 ore 
 
 
Somministrazione di vaccini costituiti da virus o batteri uccisi o inattivati o da tossoidi. 
Assunzione di farmaci. 
Possono sussistere ulteriori ragioni per il rinvio temporaneo di un donatore ai fini della protezione 
dei riceventi la donazione: la decisione relativa alla durata del periodo di rinvio spetta al medico 
veterinario  responsabile  della   selezione  e  comunque  in  accordo  alla  normativa  vigente  sui 
medicinali veterinari e rispettando i tempi di sospensione più lunghi. 
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Allegato n.5 
 
PREPARAZIONE E CONSERVAZIONE DEL SANGUE 
 
Il centro di prelievo del sangue intero destinato alla commercializzazione è costituito da locali in 
grado  di  garantire  un’adeguata  igiene  delle  procedure,  equiparati  ad  una  struttura  veterinaria 
secondo la definizione  dell’accordo Stato regione (Atti n. 1868 del 26 novembre 2003) e deve 
avere la disponibilità di particolari attrezzature di seguito elencate: 
1.  pinza multifunzione e anellini di alluminio o pinza saldatrice; 
2.  emofrigoteca a temperatura costante di 4-6 °C con registratore di temperatura, dotato di 
gruppo di continuità; 
3.  agitatore meccanico per la raccolta del sangue intero; 
4.  bilancia. 
I locali di raccolta di sangue intero devono essere autorizzati dalle ASL competenti per territorio e 
devono adottare  tutte le misure idonee a valutare e prevenire la diffusione delle malattie post- 
trasfusionali, principalmente quelle infettive. 
 
Per le operazioni di preparazione del sangue intero devono essere utilizzate sacche autorizzate dal 
Ministero della salute. 
 
Tipologie dei prodotti emotrasfusionali: 
1.  Sangue intero fresco: sangue prelevato da 6-8 ore; 
2.  Sangue intero conservato: sangue conservato oltre 6-8 ore; 
3.  Sangue  intero  in  predeposito  per  autotrasfusioni:  consiste  in  un’unità  di  sangue  intero 
prelevata al paziente cui è destinata per corrispondere a proprie esigenze terapeutiche. 
 
Allegato n.6 
 
 
ETICHETTATURA DEL SANGUE INTERO 
 
Su ciascuna sacca contenente sangue intero  dovrà essere indicato tramite apposita etichetta: 
 
1.  nome ed indirizzo della struttura di prelievo del sangue intero; 
2.  numero identificativo della donazione ; 
3.  tipo del preparato; 
4.  peso netto del preparato; 
5.  data di prelievo e preparazione; 
6.  data di scadenza del prodotto; 
7.  composizione  e  volume  della  soluzione  anticoagulante  conservante  e  delle  eventuali 
soluzioni aggiunti; 
8.  gruppo sanguigno dell’animale donatore; 
9.  modalità  e temperatura di conservazione; 
10. indicazione della specie animale; 
11. dati anagrafici del donatore. 
Nei sottoelencati  preparati trasfusionali devono inoltre essere inclusi le seguenti diciture: 
1. Sangue  intero  fresco,  sangue  intero  conservato,  Dicitura:  “  esclusivamente  per  uso 
veterinario – specie di destinazione:…… non utilizzabile a scopo trasfusionale se presenta emolisi  o  
altre  anomalie  evidenti”  “per  la  trasfusione  utilizzare  un  adatto  dispositivo munito di 
appropriato filtro” 
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2. Sangue  intero  da  predeposito  per  autotrasfusioni.  L’etichetta  di  colore  diverso  dalle 
omologhe deve indicare la dicitura: AUTODONAZIONE – STRETTAMENTE 
RISERVATA A: . Generalità del tutore dell’animale; firma del medico responsabile del salasso; 
tipo di preparato; la dicitura: “ Non utilizzare a scopo trasfusionale se presenta emolisi o altre  
anomalie evidenti”; la dicitura: “ Per la trasfusione utilizzare un adatto dispositivo munito di 
appropriato filtro” ; la dicitura “ Esclusivamente per uso autologo – prove di compatibilità ed 
esami pre-trasfusionali  NON ESEGUITI”. 
123 
 
 
 
Science Publications on National 
Journals and Proceedings of 
National Conferences 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ATTACHMENT 2 
124 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
125 
 
 
Scientific Pubblication on National Journals 
 
PEREGO R., BAGNAGATTI DE GIORGI G., SPADA E, 
DOMENICHINI G, PROVERBIO D. (2010) Dermatofitosi nella specie 
felina. Rassegna di Medicina Felina Anno 14, n° 1, pp. 7-16 
 
SPADA E., PEREGO R., BAGNAGATTI DE GIORGI G., DELLA 
PEPA A., BAGGIANI L., PROVERBIO D. (2011) Gruppi sanguigni 
nel gatto e medicina trasfusionale felina. Rassegna di Medicina Felina, 
Anno 15, N° 3, pp. 7-13 
 
SPADA E., PEREGO R., BAGNAGATTI DE GIORGI G., DELLA 
PEPA A., PROVERBIO D. (2011) Sindrome acquisita da fragilità cutanea 
felina. Rassegna di Medicina Felina, Anno 15, N° 4, pp 7-10.  
 
DOMENICHINI G., SPADA E., DELLA PEPA A., BAGNAGATTI 
DE GIORGI G., DRAGONETTI V. , PEREGO R., PROVERBIO 
D.(2012) Caratteristiche di una popolazione di gatti di colonia della città di 
Milano. Rassegna di Medicina Felina, N° 2, pp 8-15. 
 
 
 
 
 
 
 
126 
 
 
Scientific Publications on Proceedings of 
National Conferences 
 
PROVERBIO D., BAGGIANI L., PEREGO  R., MILICI A., 
DOMENICHINI G., DELLA PEPA A., BAGNAGATTI DE GIORGI 
G., FERRO E. (2010) Distribuzione dei gruppi sanguigni A, B E AB in 
gatti di razza ragdoll, Atti del LXIV Convegno Nazionale SISVet,  7-10 
settembre 2010, Asti (AL) 
 
PROVERBIO D., PEREGO R., SPADA E., BAGGIANI L., 
BAGNAGATTI DE GIORGI G., DELLA PEPA A., FERRO E. (2010) 
Confronto tra una metodica elettroforetica semi-automatica e un metodo 
biochimico per la valutazione degli isoenzimi della fosfatasi alcalina nel 
siero canino. Atti del LXIV Convegno Nazionale SISVet, 7-10 settembre 
2010, Asti (AL) 
 
PROVERBIO D., SPADA E., DELLA PEPA A., BAGGIANI L., 
PEREGO R., BAGNAGATTI DE GIORGI G, FERRO E. (2011) 
Confronto tra ELISA rapido e IFAT per la ricerca di IgG specifiche per 
Toxoplasma Gondii nel siero di gatto. Atti del LXV Convegno Nazionale 
SISVet, 7-10 settembre 2011, Tropea-Drapia (VV)  
 
BAGNAGATTI DE GIORGI G., SPADA E., BAGGIANI L., 
PEREGO R., FERRO E., ROGGERO N., PROVERBIO D.  (2012). 
“Plasma ricco in piastrine (PRP): prime esperienze di laboratorio per la 
valutazione di una metodica per l’ottenimento del PRP nel cane”  Atti del 
LXVI Convegno Nazionale SISVet, 12-14 settembre 2012, Roma, pp 229-
232.  
 
 
 
 
 
127 
 
 
 
Science Publications on Peer 
Review International Journals with 
Impact Factor 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ATTACHMENT 3 
128 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
129 
 
Scientific Publications on Peer Review 
International Journal with Impact Factor 
 
PROVERBIO D., BAGNAGATTI DE GIORGI G., DELLA PEPA A., 
PEREGO R., BAGGIANI L., SPADA E., BELLOLI A. (2011) 
Preliminary evalutation of total protein concentration and serum protein 
fraction obtained by electrophoresis of fresh and frozen wild horned viper 
serum  (Vipera ammodytes ammodytes).  Accepted for publication on 
Veterinary Clinical Pathology on December 20, 2011 
 
SPADA E., PROVERBIO D., DELLA PEPA A., PEREGO R., 
BAGGIANI L., BAGNAGATTI DE GIORGI G., DOMENICHINI G., 
FERRO E., CREMONESI F (2012) Seroprevalence of feline 
immunodeficiency virus, feline leukemia virus and Toxoplasma Gondii in 
stray cat colonies in northern Italy and correlation with clinical and 
laboratory data. Journal of Feline Medicine and Surgery, 2012 Jun;14(6), pp 
369-77 
 
PROVERBIO D., SPADA E., PEREGO R., DELLA PEPA A., 
BAGNAGATTI DE GIORGI G., BAGGIANI L. (2012) Assessment of 
blood types of ragdoll cats for transfusion purposes. Accepted for 
publication on Veterinary Clinical Pathology on 19 July 2012.  
 
SPADA E., PROVERBIO D., DELLA PEPA  A., DOMENICHINI 
G., BAGNAGATTI DE GIORGI G., TRALDI G., FERRO E. (2012) 
Prevalence of fecal-borne parasites in colony stray cats in northern Italy. 
Accepted for publication on Journal of Feline Medicine and Surgery on 11 
December 2012 
 
 
 
 
 
130 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
131 
 
 
 
Science Publications on 
Proceedings of International 
Conferences 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ATTACHMENT 4 
132 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
133 
 
Scientific Publications on Proceedings of 
International Conferences 
 
SPADA E., DELLA PEPA A., MIGLIAZZO A., BAGNAGATTI DE 
GIORGI G., PEREGO R. PROVERBIO D. (2013). “Serological and 
molecular evaluetion of Leishmania infantum infection in stray cats in a non-
endemic area in Northern Italy”. INTERNATIONAL SCIVAC 
CONGRESS – CANINE LEISHMANIOSIS AND OTHER VECTOR-
BORNE DISEASE: OUR CURRENT STATE OF KNOWLEDGE. 
MARCH 8th – 10th,  PISA, ITALY 
